A later narrative review of clinical evidence found benefits for surgical wounds and burns, but mixed results for chronic wounds.

A mechanistic review described Aloe vera as anti-inflammatory, antimicrobial, and pro-proliferative, with evidence for improved wound contraction and tensile strength.

A review of clinical trials concluded Aloe vera has been used for skin ulcers, burns, postoperative wounds, and some chronic wounds, often reducing healing time and symptoms.

A cell-proliferation study found Aloe vera accelerates wound healing by promoting fibroblast and keratinocyte proliferation and migration.

Early experimental work and clinical summaries indicate Aloe vera can reduce inflammation and speed burn healing; results vary by wound type and study design.

Cochrane review found ginseng may have trivial effects on erectile function by validated questionnaires, but may improve self-reported ability to have intercourse.

Review of ginseng and male reproductive function describes possible benefits for sexual performance, fertility, spermatogenesis, and hormonal modulation.

This review again emphasized that Arjuna may be useful in heart failure as an adjunct, but the clinical evidence is not yet robust.

This overview states that Terminalia arjuna helps reduce oxidative stress and inflammation, which are contributors to hypertension.

This review discussed mechanistic clues showing cardioprotective effects of Arjuna bark extract in isoproterenol-induced chronic heart failure in rats.

This review reported that Terminalia arjuna has been found useful in mild hypertension and other cardiovascular conditions, based on experimental and clinical evidence.

This review of cardioprotective effects described Terminalia arjuna as having hypotensive activity and potential relevance for blood-pressure control.

This study found Terminalia arjuna enhanced baroreflex sensitivity and myocardial function in chronic heart failure, suggesting autonomic and ventricular benefits.

This chapter/review noted that Terminalia arjuna may have properties useful for hypertension and described its cardiovascular and antioxidant actions.

This review summarized experimental and clinical evidence and noted that Arjuna has reported efficacy in heart failure, though extract standardization remains a major limitation.

This clinical report found Arjuna, compared with placebo, improved symptoms and signs of heart failure and improved NYHA class in patients with severe refractory heart failure.

This meta-analysis of 21 randomized trials found improvements in cardiometabolic outcomes, including a modest reduction in systolic blood pressure, supporting vascular relevance.

This review reports that Cynara scolymus may help prevent cardiovascular diseases through anti-inflammatory and antioxidant activity, and it highlights the plant’s potential to reduce vascular dysfunction.

This review summarizes evidence that artichoke leaf extract improves lipid profile and supports use in hypercholesterolemia.

This review describes artichoke as a source of bioactive compounds with cardiovascular benefits, including lipid lowering and antioxidant effects that may support vascular health.

This systematic review concluded that artichoke extract has lipid-lowering activity and can reduce total cholesterol and LDL cholesterol in some studies.

This animal study found that artichoke extract reduced plasma cholesterol and suggested that the plant could help with lipid metabolism.

This randomized, double-blind placebo-controlled trial found that artichoke leaf extract modestly reduced total cholesterol in otherwise healthy adults with mild to moderate hypercholesterolemia.

This subset analysis found that artichoke leaf extract also improved symptoms in participants with IBS who had concomitant dyspepsia.

This randomized controlled trial found that artichoke leaf extract significantly improved dyspeptic symptoms and quality of life in patients with functional dyspepsia.

This open study reported that high doses of standardized artichoke leaf extract reduced mild dyspepsia symptoms and improved upper gastrointestinal comfort.

This early endothelial-cell study found that artichoke extract protected cultured endothelial cells and monocytes from oxidative stress, a mechanism relevant to vascular protection.

This later study discusses asafoetida as a digestive aid and notes its use for postprandial fullness and bloating in functional dyspepsia.

This journal report on the same study states that asafoetida significantly reduced bloating, postprandial fullness, indigestion, and appetite-related discomfort.

This randomized, double-blinded, placebo-controlled study found that 250 mg twice daily for 30 days improved functional dyspepsia symptoms; bloating improved in 58% of the asafoetida group.

Recent broad review concluded that ashwagandha has promising potential for stress reduction, but more rigorous trials are needed.

Recent broader meta-analysis of adult mental health studies concluded ashwagandha may improve stress and depression-related outcomes, though the focus was not depression alone.

Recent broad review concluded that ashwagandha has promising potential for stress reduction, but more rigorous trials are needed.

Newer systematic review concluded ashwagandha formulations had beneficial effects on stress and anxiety.

Broader mental-health meta-analysis; found evidence supporting effectiveness for anxiety symptoms, though with heterogeneity and outlier effects.

Systematic review and meta-analysis of nine studies found significant reductions in perceived stress, anxiety, and cortisol versus placebo.

Systematic review and meta-analysis of nine studies found significant reductions in perceived stress, anxiety, and cortisol versus placebo.

Systematic review and meta-analysis; pooled five RCTs found a significant reduction in HAM-A scores, with promise for anxiety and insomnia but need for larger trials.

Systematic review and meta-analysis; nine RCTs showed significant improvements in perceived stress, anxiety, and cortisol versus placebo.

Randomized controlled study reported that standardized ashwagandha root extract improved depression and anxiety scores, suggesting benefit as an adjunct in mood symptoms.

Standardized root extract was reported to improve depression and anxiety symptoms in adults.

Randomized placebo-controlled trial in healthy adult males found improved sexual function and increased testosterone.

Acute crossover trial found improved working memory, sustained attention, and vigilance after a single ashwagandha dose.

Review of preclinical and clinical studies found that W. somniferaimproved depression symptoms in some studies, but fewer trials addressed depression than stress/anxiety.

Systematic review and meta-analysis found a small but significant improvement in sleep versus placebo, particularly at 600 mg/day and after 8 weeks.

Randomized placebo-controlled study found ashwagandha improved sleep quality in healthy adults and insomnia patients, especially in those with insomnia.

Randomized placebo-controlled study in healthy stressed adults found improved memory and focus, reduced stress, and better sleep quality.

Review of preclinical and clinical studies; reported noteworthy anti-anxiety activity in animal and human studies, but highlighted variability in extracts and dosing.

Review of current research summarized multiple trials showing reduced stress and improved sleep, mood, and cortisol outcomes.

Review of current research summarized multiple trials showing reduced stress and improved sleep, mood, and cortisol outcomes.

Randomized placebo-controlled study found significant reductions in anxiety-related outcomes and morning cortisol, suggesting HPA-axis modulation.

Pilot clinical study evaluated ashwagandha root extract in insomnia and anxiety, suggesting improvement in sleep outcomes with good tolerability.

Systematic review concluded that early clinical evidence supports cognitive benefits, especially for attention, executive function, and reaction time.

Randomized placebo-controlled study found significant reductions in anxiety-related outcomes and morning cortisol, suggesting HPA-axis modulation.

Review summarized ashwagandha’s role in male infertility, sperm quality, oxidative stress, and reproductive hormones.

Early preclinical work reported that an ashwagandha-derived sleep-promoting constituent increased non-REM sleep in mice.

Pilot study found improved memory, executive function, attention, and information-processing speed in adults with mild cognitive impairment.

Review of sexual-performance herbs highlighted ashwagandha as one of the better-supported botanicals for male vitality and virility.

Randomized pilot study found improved semen count, volume, motility, and hormones in oligospermic men after 90 days of root extract.

Preclinical work showed improved sexual behavior in male rats, supporting later human fertility studies.

A bioactivity-guided isolation study identified quercitrin and isoquercitrin as key antidiarrheal constituents and confirmed dose-dependent benefit in mouse diarrhea models.

A later article cited prior asthma work and again described E. hirta as having anti-inflammatory and antioxidant effects relevant to allergic inflammation.

This study showed the crude extract had antidiarrheal effects possibly via calcium-channel blockade, while also noting dose-dependent laxative effects at lower doses.

This paper examined Euphorbia hirtain experimental animals and found benefits against anaphylaxis, mast-cell degranulation, and bronchospasm, supporting use in allergen-induced asthma.

In neonatal asthmatic rats, E. hirta extract reduced inflammatory cells, TNF-α, IL-6, and oxidative stress and showed anxiolytic effects alongside anti-allergic benefits.

A comparative preclinical study found that ethanol and water extracts significantly reduced diarrhea and intestinal transit in rats, with ethanol extract showing stronger activity.

A 95% ethanol extract inhibited mast cell degranulation, paw edema, eosinophil accumulation, and Th2-type allergic signaling in animal models, showing strong anti-allergic potential.

Early experimental work found that aqueous leaf extract reduced gastrointestinal motility and inhibited castor-oil-induced diarrhea in rats.

Triple-blind randomized clinical trial found astragalus root extract reduced post-COVID chronic fatigue in nurses.

General reference notes astragalus is traditionally used as an immune tonic and adjunct for colds and upper respiratory infections.

Review concluded astragalus polysaccharides have broad immunoregulatory effects on immune cells, antiviral immunity, and anti-tumor immunity.

AS-IV ↑eNOS/NO via PI3K/Akt, ↓ROS/ONOO-, protects oxidative stress-induced endothelial dysfunction.

Functional-food review notes astragalus may provide benefits during disease treatment through oxidative stress reduction and immunomodulation, which are relevant to stress adaptation.

Functional-food review notes astragalus may provide benefits during disease treatment through oxidative stress reduction and immunomodulation, which are relevant to stress adaptation.

Preclinical study aimed to evaluate anti-stress effects of astragalus on repeated restraint stress-induced anxiety, learning, and memory changes in rats.

Preclinical study aimed to evaluate anti-stress effects of astragalus on repeated restraint stress-induced anxiety, learning, and memory changes in rats.

Review summarizes astragalus as a tonic adaptogen with antioxidant and immunoregulatory effects relevant to stress resilience.

Review summarizes astragalus as a tonic adaptogen with antioxidant and immunoregulatory effects relevant to stress resilience.

ASP/TEA (HHcy rats): ↑Ach relaxation/NO/NOS, ↓H2O2/O2-, MMP-2/9, ↑SOD/CAT, ↓BP/remodeling.

Mouse study found AM improved exercise performance and reduced fatigue markers such as lactate and ammonia.

Cell study found astragalus extract activated macrophages and increased inflammatory mediator release via heparanase.

TFA (10/20 μmol/L) ↑Ach-induced vasorelaxation in FFA-injured rat aortas, ↑NOx, ↓NF-κB activation.

Traditional Chinese Medicine documentation of Peucedanum praeruptorum (Qianhu/Bai Hua Qian Hu) use for respiratory ailments. Historical documentation: First recorded use in Wei-Jin and South-North Dynasties (AD 220-450) in Mingyi Bielu (《名医别录》). Ancient texts documenting use: (1) Rihuazi Bencao (《日华子本草》) (Five Dynasties, AD 908-923); (2) Compendium of Materia Medica (《本草纲目》) (Ming Dynasty, AD 1578); (3) Illustrated Classics of Materia Medica (《本草图经》) (Song Dynasty, AD 1061). Recorded indications: Colds, headaches, coughs, asthma, chest congestion. Contemporary use: Chinese Pharmacopoeia 2020 officially recognizes P. praeruptorum root as Qianhu; multiple botanical names including yimacai, luoguicai, shuiqianhu, shuifangfeng, shanyuansui, guanqianhu, shanduhuo. Modern clinical applications: Chronic respiratory failure, acute bronchitis, iridocyclitis after cataract surgery. TCM formulation integration: Used in 189+ pharmaceutical preparations, 525+ classical prescriptions; commonly combined with Mentha haplocalyx, Arctium lappa, Platycodon grandiflorum for external wind-heat and cough treatment; combined with Citrus reticulata, Pinellia ternata, Prunus armeniaca for cough and chest congestion management. Registered pharmaceutical preparations: "Tong Xuan Li Fei Ke Li" and "Tong Xuan Li Fei Pian" (accredited by National Medical Products Administration) marketed in China for cough treatment. Traditional mechanism: Recognized to "disperse wind-heat, reduce cough and phlegm, and dissipate adverse Qi" according to TCM classification. Conclusion: P. praeruptorum represents 1500+ year documented traditional cough remedy integrated into extensive pharmaceutical formulation systems.

Experimental animal pharmacological study evaluating antitussive and expectorant effects of Peucedanum praeruptorum Dunn extracts in cough models. Study design: Extract preparation: P. praeruptorum roots from Guangxi, China extracted with water and ethyl acetate at concentrations 5.0 g/kg and 10.0 g/kg. Animal models: Mice and guinea pigs receiving intragastric administration once daily for 7 days. Cough induction models: (1) Ammonia-induced cough in mice; (2) Histamine phosphate-induced asthma in guinea pigs. Results—Antitussive efficacy in ammonia-induced cough (mice): Extract significantly prolonged incubation period of cough (time to cough onset increased) compared to controls; decreased frequency of cough episodes significantly. Results—Antitussive efficacy in histamine-induced asthma (guinea pigs): Extract prolonged incubation period of asthma induced by histamine phosphate in guinea pigs (p<0.05). Results—Expectorant effect: Aqueous extract of P. praeruptorum demonstrated significant expectorant activity based on phenol red flushing test of respiratory tract—indicating enhanced mucus secretion and clearance. Results—Variety comparison: White, fine, and red varieties of P. praeruptorum showed superior expectorant activity (phenol red output) compared to other P. praeruptorum varieties. Dosing: Raw material administered at 20 g/kg solution via intragastric capillary tube method in rat phenol red expectorant assay. Mechanism proposed: Coumarins and pyranocoumarins (praeruptorins A, B, C) identified as active antitussive compounds; expectorant mechanism involves enhanced mucus secretion supporting productive cough. Conclusion: P. praeruptorum aqueous and ethyl acetate extracts demonstrate significant antitussive effect in animal cough models and expectorant activity supporting phlegm elimination.

Mechanistic study examining Korean traditional medicine application of Peucedanum species root extract (from P. praeruptorum and P. decursivum) for allergic lung inflammation and anti-asthmatic effects. Study design: Korean traditional use: Peucedani radix (root of P. praeruptorum Dunn or P. decursivum Miq. Maxim.) long used in Korea to "eliminate sputum, relieve cough, and reduce bronchus contraction." Animal model: Ovalbumin (OVA)-induced allergic asthma in mice; airway hyperresponsiveness assessment. Extracts tested: Peucedani radix (PR) extract—traditional Korean medicine preparation. Results—Inflammatory cell reduction: PR treatment decreased inflammatory cell infiltration in bronchoalveolar lavage fluid (BALF) compared to untreated asthma model. Results—Mucus production reduction: PR treatment significantly reduced mucus production in airway epithelium (reduced airway epithelial mucin staining). Results—Eosinophil reduction: Decreased eosinophilia (reduced eosinophil counts) in BALF of PR-treated mice versus untreated asthma group. Results—Type 2 cytokine reduction: PR treatment significantly decreased Type 2 cytokines (IL-4, IL-5, IL-13) in BALF—indicating Th2 pathway suppression. Results—Histamine reduction: Reduced histamine levels in BALF of PR-treated mice. Results—CD4 T cell activation: PR treatment diminished activated CD4 T cells (CD4+CD25+ cells) in lung tissue and decreased GATA-3 transcription factor expression (critical for Th2 differentiation). Results—Th2 polarization in vitro: PR extract reduced Th2 cell activation in vitro using Th2 polarization system (CD4+ T cell differentiation toward Th2 phenotype suppressed). Results—Anti-inflammatory pathway: Evidence indicates TLR4/NF-κB pathway modulation as mechanism for anti-inflammatory effects reducing cough-inducing airway inflammation. Conclusion: PR extract demonstrates anti-inflammatory effects on allergic lung inflammation through suppression of Th2 cell activation and Type 2 cytokine production, validating traditional Korean medicine use for cough and asthma relief.

More recent integrative review summarizes chemical components and pharmacology, supporting therapeutic effect in refractory dermatoses such as vitiligo while noting safety concerns.

Review highlights P. corylifolia as an extensively used medicinal plant for vitiligo and notes its key anti-vitiligo phytochemicals.

Clinical formulation study found a hydrophilic ointment with Psoralea corylifolia seed powder improved repigmentation of small circular vitiligo lesions over 12 weeks.

Recent review and meta-analysis show Berberis species may improve glycemic control and cardiovascular risk factors in type 2 diabetes, though evidence remains heterogeneous.

Review notes clinical and preclinical evidence that Berberisspecies improve glycemic control and insulin sensitivity.

Clinical trial found Berberis vulgaris root extract improved fasting blood sugar, fructosamine, and HbA1c in type 2 diabetes.

Review of B. vulgarisand berberine in metabolic syndrome summarizes strong antidiabetic and lipid-lowering evidence and calls for better clinical trials.

Animal study found aqueous and saponin extracts of B. vulgarislowered glucose and improved cholesterol/triglycerides in streptozotocin-diabetic rats.

Review summarizes in vitro antimicrobial findings, preliminary animal/human work, and clinical trials, concluding clinical evidence is still too limited for widespread use.

Randomized, double-blind controlled comparative effectiveness trial protocol evaluating uva-ursi as an initial treatment to reduce antibiotic use without increasing symptom burden or complications.

Study protocol for a randomized controlled trial testing whether uva-ursi and/or ibuprofen can reduce UTI symptoms and antibiotic use in adult women.

This mechanistic study found bergamot polyphenols may lower cholesterol by affecting AMPK activation and reducing cholesterol uptake in intestinal cells.

This early review summarized clinical and preclinical evidence that bergamot polyphenols can reduce serum cholesterol and improve lipid profiles.

Review concluded Vacciniumspecies have bioactivity that may help reduce blood glucose, oxidative stress, and inflammation in diabetes and complications.

Randomized crossover trial in type 2 diabetes found a standardized bilberry extract reduced postprandial glucose and insulin after a glucose challenge.

Herbal monograph noted bilberry has been reported to lower blood glucose and has anti-inflammatory and lipid-lowering effects.

This article notes that ajwain improves digestion by stimulating gastric juice secretion and is used for indigestion and bloating.

This traditional-medicine overview states ajwain is commonly used for digestive disorders such as flatulence and dyspepsia.

This more recent study reports anti-inflammatory and metabolic effects of Atractylodes lancea in metabolic syndrome rats, which may be relevant to gastrointestinal and abdominal discomfort but is indirect for bloating.

This mouse study showed that Atractylodes lancea extract helped recover intestinal flora imbalance and could influence bile acid and amino acid metabolism, supporting a digestive mechanism relevant to bloating.

This animal study found that Atractylodes lancea rhizome extract and its volatile component β-eudesmol stimulated gastric emptying or small intestinal motility in mice, which could help reduce bloating from delayed digestion.

This study suggests black cumin seeds can protect against septic arthritis by modulating immune and inflammatory responses.

This review summarizes evidence that Nigella sativaand thymoquinone may help prostate health through antioxidant, anti-inflammatory, and anticancer mechanisms.

This journal article notes that Nigella sativademonstrates anti-inflammatory, anti-histaminic, and antimicrobial effects that may help rhinosinusitis and allergic rhinitis symptoms.

This journal article notes that Nigella sativademonstrates anti-inflammatory, anti-histaminic, and antimicrobial effects that may help rhinosinusitis and allergic rhinitis symptoms.

This newer open-label randomized trial found that a topical mixture of Nigella sativa powder and vinegar may help mild to moderate acne, though the small sample and short duration limit certainty.

This clinical trial found that Nigella sativasupplementation significantly increased estradiol and improved the vaginal maturity index in postmenopausal women, though FSH did not change significantly.

This newer randomized controlled trial found that Nigella sativa seed extract increased estradiol and significantly reduced total PMS scores versus placebo.

This review summarizes multiple clinical and preclinical studies showing that black seed has anti-inflammatory potential across conditions, including some relevant to women’s health.

This clinical trial in postmenopausal women found that 910 mg/day and 1,365 mg/day of Nigella sativaseed extract for eight weeks significantly increased estradiol and vaginal maturity index, but not FSH.

This recent study summary also reports a reduction in systolic and diastolic blood pressure, plus lipid improvements, in postmenopausal women.

This more recent review describes N. sativa as a promising adjunct therapy for cardiovascular risk factors, including dyslipidemia.

This animal study showed Nigella sativaoil restored ovarian and uterine endocrine signals after toxicity, which is biologically interesting but not endometriosis-specific.

This study on quercetin-loaded black cumin seed oil nanoemulsion reports protective and antioxidant effects in testosterone-induced BPH and supports the prostate-protective role of black cumin oil.

This randomized, double-blind, placebo-controlled study reported that standardized Nigella sativa oil improved allergic rhinitis symptoms in adults over 15 days.

This meta-analysis of randomized trials found that Nigella species improved allergic rhinitis outcomes, including total nasal symptom scores, but cautioned that more high-quality trials are needed.

This randomized, double-blind, placebo-controlled study reported that standardized Nigella sativa oil improved allergic rhinitis symptoms in adults over 15 days.

This meta-analysis of randomized trials found that Nigella species improved allergic rhinitis outcomes, including total nasal symptom scores, but cautioned that more high-quality trials are needed.

This systematic review found that Nigella sativa relieved pain and improved physical function in joint-related conditions across six RCTs.

This systematic review of randomized controlled trials found that Nigella sativa relieved pain and improved physical function in joint-related conditions, with 370 participants across six RCTs.

This animal study found that Nigella sativa oil helped restore hormonal levels and endocrine signals in female rats after sodium fluoride exposure, supporting a hormone-balancing mechanism.

This meta-analysis of 34 studies and 2278 participants found significant reductions in total cholesterol, LDL, and triglycerides, with an increase in HDL.

RCT (n=120 postmenopause): NS oil 1000 mg/day ↑femoral neck BMD; combo with curcumin ↑lumbar BMD (6 months).

This animal study reported that Nigella sativa plus vitamin E increased endometrial thickness in mice, showing an effect on uterine tissue but not on endometriosis lesions.

This review summarizes evidence that N. sativa can reduce inflammation and acne lesion counts, supporting its dermatologic use.

This systematic review and meta-analysis reported that N. sativa powder and oil both lowered systolic blood pressure, with oil appearing more effective.

This infertility review includes reproductive-system findings for Nigella sativa, but again no direct endometriosis trial evidence.

This randomized controlled trial in women with vulvovaginal candidiasis found that a Nigella sativa–honey vaginal cream improved symptoms and fungal culture results.

This botanical review explains that anti-fibroid evidence exists for some herbs, but Nigella sativa is not supported by direct uterine fibroid trial data in the literature summarized.

This review chapter summarizes that experimental and clinical studies show Nigella sativa may alleviate allergic rhinitis symptoms through immunomodulatory effects.

This review chapter summarizes that experimental and clinical studies show Nigella sativa may alleviate allergic rhinitis symptoms through immunomodulatory effects.

This 2022 skin-disease review also includes vitiligo among conditions where Nigella sativamay be helpful, though evidence remains limited.

This review/meta-analysis found that Nigella sativaproducts may be effective for acne among other skin disorders, though heterogeneity limits certainty.

This study found that Nigella sativaoil reduced knee osteoarthritis pain and lowered acetaminophen use, with no major adverse effects.

This adjuvant-therapy study examined whether black seed oil improved symptoms and inflammatory biomarkers in rheumatoid arthritis.

This review compiled animal and human studies and concluded that N. sativahas consistent hypo-cholesterolemic effects.

Oral N. sativa oil (2.5 mL TID, 4 weeks) ↓WOMAC pain/stiffness/function, VAS pain vs placebo in knee OA (n=116).

This animal study found that Nigella sativa seed oil reduced prostate weight, PSA, DHT, and oxidative stress markers in a testosterone-induced BPH model, suggesting anti-inflammatory and anti-BPH effects.

This review concluded that black cumin’s bioactive compounds have anti-inflammatory and protective effects in rheumatoid arthritis, based on animal and human studies.

This clinical trial found that local Nigella sativa oil reduced the severity of most PMS symptoms, though depression and abdominal bloating were less affected.

This review concluded that Nigella sativa has analgesic, anti-inflammatory, and immunomodulatory effects relevant to rheumatoid arthritis, supported by human clinical trials.

This review summarizes clinical and animal evidence and concludes that N. sativahas meaningful antihypertensive potential through several mechanisms.

This randomized double-blind clinical trial found that a topical Nigella sativa hydrogel significantly improved acne severity, reduced comedones/papules/pustules, and improved acne disability scores.

This experimental paper found thymoquinone-rich black cumin oil improved antioxidant status and reduced inflammatory markers in adjuvant-induced arthritis.

This in-vitro study reported that Nigella sativaextract could help remove Candida albicans plaque from acrylic resin, though it was weaker than nystatin.

The PubMed abstract for the same study reports the same finding: significant repigmentation after 6 months of topical use.

This report on human and experimental data states that Nigella sativa may reduce inflammatory biomarkers and supports its anti-inflammatory potential.

This review of clinical trials on black seed discusses several female reproductive uses, but does not provide direct evidence for endometriosis treatment.

This review of clinical trials summarizes that black seed has shown repigmentation effects in vitiligo and other autoimmune skin conditions.

This review of clinical trials notes that black seed has been used in women’s health studies and describes an improvement in vulvovaginal inflammation symptoms when combined with clotrimazole.

This crossover clinical trial found topical Nigella sativa oil reduced knee osteoarthritis pain more than oral acetaminophen in elderly participants.

This randomized double-blind placebo-controlled trial in obese women found that Nigella sativaoil plus a calorie-restricted diet significantly lowered TNF-α and hs-CRP, markers of systemic inflammation.

This meta-analysis found that Nigella sativa lowered both systolic and diastolic blood pressure, with a larger effect on systolic pressure.

N. sativa oil (2-6%) ↓mortality/viral titer, ↑weight/IFN-γ/IgG in H9N2-infected turkeys.

Topical N. sativa oil (1 cc TID, 3 weeks) ↓VAS pain vs acetaminophen (p<0.05), effective for knee OA pain (n=40).

This controlled trial in perimenopausal women found that Nigella sativa reduced menopausal symptom severity and improved some quality-of-life measures, while also improving LDL cholesterol and blood glucose.

This review reports that Nigella sativacomponents can inhibit Candida and may complement conventional antifungal therapy.

This laboratory/animal-focused review summarizes early evidence that Nigella sativainhibits Candida, including reduced fungal burden in infected mice.

This randomized double-blind trial found that topical Nigella sativa oil improved vitiligo lesions more than fish oil over 6 months.

This randomized trial found that Nigella sativaimproved lipid profiles in menopausal women, lowering total cholesterol, LDL, and triglycerides while increasing HDL.

NS (800 mg/kg, 12 weeks) ↑tibial CBT/TBT/BV/TV, ↓ALP/TRAP, reverses OVX osteoporosis histology.

This review of Nigella sativa notes broad anti-inflammatory, antioxidant, and smooth-muscle effects, but it does not provide direct clinical evidence for uterine fibroids.

This randomized, double-blind study in healthy volunteers found that black seed oil lowered blood pressure compared with placebo over 8 weeks.

This in-vitro study found aqueous, methanolic, and chloroform extracts of Nigella sativa had antifungal activity against Candida albicans, with methanolic extract strongest.

Review: NS/TQ ↑osteoblast proliferation/ossification, ↓osteoclasts, blocks NF-κB/cytokines, reverses diabetes/OVX osteoporosis.

This clinical study found that Nigella sativa reduced nasal congestion, itching, runny nose, sneezing attacks, turbinate hypertrophy, and mucosal pallor within the first two weeks.

This clinical study found that Nigella sativa reduced nasal congestion, itching, runny nose, sneezing attacks, turbinate hypertrophy, and mucosal pallor within the first two weeks.

This study reported that Nigella sativaoil improved symptoms and reduced pain in rheumatoid arthritis patients.

This animal study found powdered black cumin reduced serum cholesterol, triglycerides, and LDL in rats, with only a small HDL increase.

This news item reports that thymoquinone from black seed oil can suppress the growth of aggressive prostate cancer cells in vitro, supporting mechanistic prostate research.

NS (400 mg/kg) & TQ (50 mg/kg, 12 weeks) ↓hyperglycemia, ↑insulin/beta-cell area, improved sciatic nerve histology/myelin in STZ-diabetic rats.

This older study found that Nigella sativa could reduce menstrual pain through anti-inflammatory effects, which may be relevant to endometriosis symptom management but is not direct evidence.

A modern review summarizes traditional fever use, phytochemistry, pharmacology, and toxicity, noting that the herb is commonly used as a febrifuge in East Asia.

In a rat model of LPS-induced sepsis, aqueous root extract inhibited NF-κB activation and IκBα degradation, supporting anti-inflammatory effects relevant to fever/infection.

This paper states that Dichroa febrifuga roots have been used for centuries against malarial fevers and describes its historical febrifuge use.

Review of berry-based supplements and foods concluded they generally have beneficial effects on cognition, memory performance, and brain perfusion.

Randomized trial in older adults at risk for dementia found blueberry supplementation increased brain activation during a working-memory task, suggesting improved neurovascular function.

Review summarized human observational, clinical, animal, and mechanistic research and concluded blueberries/anthocyanins may support neuroprotection and cognitive health.

Systematic review of 11 studies found blueberry interventions may improve delayed memory and executive function in children and older adults, but evidence for working memory was weaker.

Review/website summary states suma is used for chronic fatigue and stress, but evidence is mostly traditional and inconclusive.

Experimental study investigated anti-inflammatory effects of Pfaffia paniculata in rats, not fatigue directly.

Preliminary research on burdock root peptides found antibacterial, antibiofilm, and antioxidant activity, and the resulting dressing showed anti-acne potential in skin models.

This observational study found that homeopathic Lappa improved acne lesion counts, GAGS scores, and acne-related quality of life, with the strongest effect in inflammatory acne.

A recent clinical report found that Petasites hybridusreduced monthly headache days by at least 50% in many migraine patients and was well tolerated.

A literature review found that five placebo-controlled studies involving 488 patients showed butterbur was superior to placebo for migraine prophylaxis and generally well tolerated.

A review article describes the clinical evidence for butterbur, summarizes mechanisms such as CGRP inhibition and anti-inflammatory effects, and notes that Petadolex is the main extract studied in trials.

A randomized trial found that standardized butterbur root extract reduced migraine attack frequency more than placebo over 4 months, supporting preventive use.

This study evaluated cajuput oil as an adjuvant in mild and moderate COVID-19 and noted cough was a common symptom in the treatment group, supporting its traditional respiratory use.

This paper reported that Melaleuca cajuputi essential oil contains major compounds with inhibitory activity against ACE2 and SARS-CoV-2 targets, suggesting potential usefulness for respiratory infection support rather than congestion alone.

Review noting traditional use of camphor from C. camphorafor congestion, with emphasis that more systematic studies are still needed.

Review-style paper describing camphor as a traditional cold remedy used for chest congestion and related inflammatory respiratory complaints.

Early human vapor study: camphor inhalation produced a cold sensation and subjective improved airflow, but no measured reduction in nasal resistance.

This study suggests that exosome-encapsulated small RNAs from Artemisia capillaris may have therapeutic potential in NAFLD and related liver inflammation.

This later review/article continues the liver-disease theme and explains that A. capillaris is used traditionally for jaundice and liver dysfunction because it promotes bile secretion and protects the liver.

This review summarizes the herb’s hepatoprotective, choleretic, antioxidant, anti-inflammatory, antifibrotic, antiviral, and antitumor activities across multiple liver diseases.

A microbiology-focused paper describes the plant as traditionally used as an antidiarrheal and reports antimicrobial activity against diarrheagenic E. coli, which may support its GI use.

A review of carob pods states that the fruit has long been used in Mediterranean folk medicine for gastrointestinal disorders, including diarrhea.

Comprehensive mechanistic and clinical review of Ricinus communis medicinal applications including constipation management. Active constituent identified: Ricinoleic acid as primary pharmacologically active fatty acid. Constipation mechanism: Dual action involving (1) surfactant effect reducing fluid/salt/electrolyte absorption in small intestine, (2) stimulation of peristalsis through intestinal smooth muscle contraction. Multiple therapeutic domains examined: Antihelmintic (parasitic worm expulsion), anticonvulsant (seizure reduction), analgesic (pain relief), anti-inflammatory, free radical scavenging, larvicidal (mosquito control), asthamatic support. Constipation-specific evidence: Clinical documentation of laxative efficacy; however, review notes insufficient evidence for most traditional off-label uses. Safety profile: FDA designation as safe and effective for approved constipation indication. Toxicity consideration: Castor seeds contain ricin toxin (dangerous); however, castor oil extraction process completely removes ricin. Purified castor oil confirmed completely safe for human consumption with negligible toxic effects, no genotoxic effects.

FDA regulatory assessment and clinical documentation of castor oil as an approved stimulant laxative for temporary constipation relief. Historical use: Used for over 100 years in clinical practice for constipation management. Mechanism: Ricinoleic acid (primary active component) activates intestinal smooth muscle receptors promoting peristalsis and bowel movement. Onset of action: 6-12 hours typically. FDA approval status: Approved as safe and effective stimulant laxative, though use has declined due to development of more effective modern laxatives with better safety profiles. Current clinical application: Primary indication for bowel preparation before colonoscopy and other diagnostic procedures requiring bowel evacuation. Off-label historical uses (lacking scientific evidence): wound healing, arthritis, headache relief, menstrual cramps, labor induction. Special populations: Contraindicated in pregnancy due to risks of uterine contractions; use during breastfeeding requires caution; pediatric use avoided in neonates.

European Medicines Agency (EMA) regulatory assessment report on castor oil preparations for constipation management. Comprehensive evaluation of: (1) Clinical evidence from trials; (2) Safety and efficacy assessment; (3) Recommended indications and duration of use. Documentation: EMA-approved indications for castor oil preparations are limited to short-term use as laxatives for occasional constipation in adults. Safety determination: Castor oil medicines approved for adult use only, with explicit recommendation AGAINST continuous use exceeding one week without medical supervision. Mechanism summary: Ricinoleic acid reduces absorption of fluid and salts in small intestine, increases stool water content, and stimulates intestinal movement. Clinical evidence reviewed: Two formal clinical studies examined in assessment showed definitive laxative effects in constipated patients. Recommended dosage: Adult regimens specified. Adverse effects documented: Abdominal cramping, diarrhea, nausea, vomiting, electrolyte disturbances. Patient counseling: Instruction on proper administration and identification of contraindications mandatory. Conclusion: EMA approves castor oil for short-term occasional constipation relief in adults with specific safety parameters and duration limits.

Double-blind randomized molecular mechanism study using transgenic mice models to elucidate castor oil's laxative mechanism of action. Methodology: Wild-type mice (normal), EP3 receptor-deficient mice, and EP4 receptor-deficient mice given oral castor oil or ricinoleic acid. Measurements: Diarrheal response onset timing, duration, intensity, and response to other laxative classes. Molecular evaluation: EP3 and EP4 receptor expression patterns; receptor-specific signaling pathways. Results: Wild-type mice developed strong diarrhea starting ~30 min post-administration lasting ~2 hours. EP3 receptor-deficient mice showed COMPLETE LAXATIVE UNRESPONSIVENESS to ricinoleic acid (p<0.05). EP4 receptor-deficient mice responded normally to castor oil like wild-type (no difference). Critical control: EP3-deficient mice remained responsive to other laxative mechanisms (5-HTP, PEG3000) with normal response magnitude. Mechanism confirmation: COX-1 and COX-2 inhibitors did NOT block ricinoleic acid laxative effects, confirming direct EP3 activation rather than indirect prostanoid synthesis. Uterine effects: EP3-receptor-deficient pregnant mice showed NO uterine contractions from ricinoleic acid while wild-type controls exhibited significant labor-mimicking contractions. Intestinal smooth muscle cellular localization: Only smooth-muscle-specific EP3 receptors (not epithelial cell EP3) mediate laxative effects. Conclusion: Ricinoleic acid-induced laxation specifically requires EP3 prostanoid receptor activation on intestinal smooth muscle cells—the exact molecular mechanism responsible for centuries of castor oil clinical efficacy.

A review of in vivo studies found that cat’s claw modulates immune pathways and inflammation, with many extracts showing low toxicity.

Comprehensive experimental animal study investigating immunomodulatory and immune cell effects of Uncaria tomentosa extract in vivo and in vitro with detailed immune cell phenotype analysis and dose-response evaluation. Study design: Double-blind randomized animal model with both in vivo oral administration and in vitro lymphocyte culture; male BALB/c mice receiving U. tomentosa or placebo with immunotoxicity and immunomodulatory assessment. In vivo protocol: U. tomentosa hydroethanolic extract (1% total alkaloids) administered orally daily at 125, 500, and 1,250 mg/kg for 28 days; immune cell phenotypes, organ weights, and systemic toxicity assessed. In vitro protocol: Lymphocytes incubated with 10–500 μg/mL extract for 48 hours; cell viability, cytokine production, and immune cell subset analysis performed. Results—No systemic toxicity: U. tomentosa did not change body weight of animals but increased weight of liver, spleen, and kidneys—no systemic toxicity despite organ system engagement. Results—Extract not lymphocyte-toxic: Extract was not toxic to lymphocytes and increased cell viability—immunomodulatory rather than immunosuppressive effect. Results—CD4+ T lymphocyte elevation: Extract increased concentration of CD4+ T lymphocytes (helper T cells)—fundamental immune cell enhancement. Results—Th2 cytokine profile shift: Significant increase in IL-4 and IL-5 production with strong inhibition of IFN-γ and IL-2—Th2 immune polarization away from pro-inflammatory Th1 profile. Results—TNF-α selective elevation: TNF-α levels increased only at highest dose (100 μg/mL)—dose-dependent pro-inflammatory response without universal TNF elevation. Results—CD45RA+ B lymphocyte elevation: 1,250 mg/kg dose increased CD45RA+ B lymphocyte concentration—naive B cell population expansion supporting diverse antibody response capacity. Results—Immune system modulation pattern: Dose-dependent immunomodulatory effects indicating controlled immune enhancement without indiscriminate immune stimulation. Mechanism proposed: U. tomentosa promotes Th2 immune polarization (IL-4, IL-5 production) while inhibiting Th1 pro-inflammatory pathway (IFN-γ, IL-2 reduction)—supporting immune deviation appropriate for Th1-mediated disorders (excessive pro-inflammatory conditions). Conclusion: U. tomentosa demonstrates dose-dependent immunomodulatory activity promoting Th2 immune cell profile and CD4+ T lymphocyte elevation—establishing potential for Th1 immune-mediated disorder management (autoimmune, excessive inflammation) through controlled immune system modulation with low toxicity profile.

In a mouse model of listeriosis, cat’s claw increased myeloid progenitor reserve and altered cytokine signaling, suggesting immune modulation that may help regulate inflammation.

Landmark animal model study establishing immunomodulatory effects of Uncaria tomentosa extract through immune cell modulation and cytokine polarization in listeriosis model. Study design: Experimental investigation of U. tomentosa immunomodulatory effects in male BALB/c mice infected with Listeria monocytogenes; immune cell production and cytokine measurement assessed over infection timeline. Animal model: Male BALB/c mouse model of listeriosis (bacterial infection model assessing immune response). Intervention protocol: U. tomentosa dry extract (1% total alkaloid content) administered orally at 10, 50, 100, 150, and 200 mg/kg doses for 7 days prior to bacterial infection. Results—Myeloid progenitor cell elevation: Treatment with 100 mg/kg U. tomentosa increased number of myeloid progenitor cells in bone marrow—reserve immune cell population supporting infection resistance. Results—IL-1 reduction at 72 hours: 100 mg/kg dose decreased IL-1 levels at 72 hour timepoint post-infection—pro-inflammatory cytokine suppression. Results—IL-6 elevation maintained: U. tomentosa maintained elevated IL-6 levels throughout experiment duration—immune signaling for immune cell recruitment and differentiation. Results—Colony-stimulating factor (CSF) production: 100 mg/kg dose upregulated CSF production—bone marrow signaling supporting WBC production and immune reserve. Mechanism proposed: U. tomentosa indirectly modulates immune activity through inducing greater myeloid progenitor reserve in bone marrow as result of biologically active cytokine release (CSF, IL-1, IL-6)—preparatory immune enhancement for infection resistance. Conclusion: U. tomentosa demonstrates immunomodulatory effects through bone marrow myeloid progenitor elevation and CSF production—supporting immune cell reserve and infection-resistance capacity through indirect immune modulation mechanisms.

Traditional and early pharmacology work shows cat’s claw has antioxidant and anti-inflammatory activity in vitro and in vivo, including protection against indomethacin-induced gastritis and suppression of TNF-alpha and nitrite production.

Traditional ethnomedicinal documentation of Uncaria tomentosa (cat's claw/una de gato/ungurahui) use for immune support and inflammatory disease management spanning 1000+ years across Amazonian indigenous populations and Peruvian/Brazilian folk medicine systems. Historical Amazonian documentation (1000+ years): U. tomentosa documented in traditional Amazonian indigenous medicine as "una de gato" (cat's claw in Spanish) and traditional remedy for inflammatory disease management, infection recovery, and general immune support and vitality. Traditional Peruvian/Brazilian documentation: Established use in Peruvian and Brazilian folk medicine for anti-inflammatory support, immune system strengthening, general vitality restoration, and recovery from illness and immune challenges. Traditional preparation methods: Bark and root decoctions prepared through traditional boiling; herbal tea infusions prepared from dried bark/root material; contemporary preparations as supplement capsules, tablets, tinctures, and liquid extracts (typically standardized to alkaloid content). Folk medicine applications: Enhance immune system function and resistance to infection; support recovery from illness and immune challenges; manage inflammatory conditions and chronic inflammation; traditional immune tonic for general health support; support during antibiotic or pharmaceutical treatment. Traditional mechanism: Believed to strengthen immune system function; enhance resistance to infection and disease; provide antioxidant and anti-inflammatory support; modulate inflammatory mediators and immune cell activity. Contemporary traditional use: Continues in Amazonian indigenous medicine centers, Peruvian and Brazilian folk medicine practice, and contemporary Latin American herbalism; widely used as immune-support supplement in international markets; included in Brazilian National Health System (SUS) essential medicines list. Regulatory documentation: Recognized in Peruvian pharmacopeias; included in Brazilian Ministry of Health essential medicines list; European Medicines Agency (EMA) assessment completed; established regulatory recognition across multiple regions. Documented efficacy observations: Indigenous and traditional practitioners note effectiveness for immune support and recovery from immune challenges; enhanced resistance to infection reported; inflammatory condition improvement observed. Commercial availability: U. tomentosa stem bark extracts and preparations widely available in Latin American markets and international supplement markets; standardized extracts with documented alkaloid content (0.26-2.57% pentacyclic oxindole alkaloids) available. Conclusion: U. tomentosa represents immune-support botanical with 1000+ year documented traditional use specifically for inflammatory disease management and immune enhancement across Amazonian indigenous and Peruvian/Brazilian folk medicine traditions.

Methanol celery root extract ↓AST/ALT/ALP/TNF-α/IL-1β, ↑TAC/GSH, ↓ROS/TBARS in APAP liver toxicity rats.

Methanolic root extract (200/400 mg/kg) ↓liver superoxide/TP/OSI, ↑GPx/SOD in adjuvant arthritis rats.

A top-down phytochemical study found that Centaurium erythraea decoctions contain secoiridoid glycosides and xanthones, and it reported acetylcholinesterase-inhibitory activity that could help explain traditional use for digestive sluggishness.

The European Medicines Agency summary states that laboratory studies suggest appetite- and digestion-stimulating effects, but the evidence is limited and approvals are largely based on long-standing traditional use.

Systematic-style review of clinical studies found most included articles concluded chamomile reduced anxiety, though study quality varied.

Phytochemical analysis of chamomile (Matricaria recutita) constituents responsible for anti-allergic effects. Identified key active components: alpha-bisabolol (15-35% in essential oil), bisabolol oxides A & B (20-50% in essential oil), chamazulene, apigenin, quercetin, and other flavonoids. These compounds suppress mast cell-derived inflammatory mediator release and stabilize mast cell membranes. Topical use of M. recutita extract demonstrated low incidence of adverse effects. Documented anti-inflammatory properties support therapeutic application in allergic dermatitis and contact dermatitis conditions.

Open-label follow-up study found chamomile remained beneficial over 8 weeks in moderate-to-severe GAD.

Preclinical and translational review noted chamomile’s anxiolytic rationale via flavonoids such as apigenin and GABA-related mechanisms.

In vitro and in vivo studies examining anti-allergic properties of German chamomile volatile and non-volatile components. Assessment of anti-inflammatory effects using models of mast cell-mediated allergic reactions and passive cutaneous anaphylaxis (PCA). Results demonstrated that both volatile (essential oil) and non-volatile components exhibited significant anti-inflammatory and anti-allergic effects through complementary mechanisms. Volatile oils provided rapid mast cell membrane stabilization while non-volatile compounds sustained long-term anti-inflammatory activity.

Experimental animal study (BALB/c mice and Sprague-Dawley rats) investigating methanol extract of M. recutita for anti-allergic activity using mast cell-mediated allergy models. Methods: Protective effects against compound 48/80-induced anaphylaxis and pruritus models were tested. Mast cell degranulation, histamine release, and inflammatory mediators measured. Results: Methanol extract showed inhibitory effects on compound 48/80-induced anaphylaxis and dose-dependent anti-pruritus effect via mast cell degranulation inhibition. Mast cell membrane stabilization observed at 100-400 mg/kg doses. Dose-dependent reduction in histamine release from blood, rat peritoneal fluid, and bronchoalveolar lavage (BAL) fluid. Serum, peritoneal, and BAL nitric oxide (NO) levels significantly decreased. Conclusion: Potent anti-allergic activity through histamine release inhibition from mast cells and NO suppression.

ClinicalTrials registry entry showing the rationale for long-term chamomile therapy after prior short-term anti-anxiety findings.

Randomized placebo-controlled trial found chamomile extract reduced anxiety symptoms in mild-to-moderate GAD.

This study directly tested NDGA from Larrea tridentata in a mouse skin inflammation model and found reduced edema, oxidative stress, and inflammatory cell infiltration.

Meta-analysis of clinical trials found Vitex agnus-castussuperior to placebo for PMS treatment, though study heterogeneity was high.

Systematic review of randomized controlled trials found most PMS studies favored Vitexover placebo or active comparators, with mild and infrequent adverse events.

Randomized placebo-controlled trial found dry extract of agnus castus fruit effective and well tolerated for PMS symptom relief.

T. chebula powder ↑intestinal transit time (charcoal meal) in mice; mild stimulatory without disrupting gut integrity.

Aqueous seed extract ↑ileal frequency/tension (Ca²⁺-mediated), ↑fecal number/water content, intestinal transit vs morphine constipation in rats.

BFC extract ↑cough latency, ↓frequency (ammonia mice), ↑phenol red expectoration, ↓xylene ear swelling (anti-inflammatory).

Alkaloids (imperialine, verticinone, verticine, chuanbeinone) ↓cough frequency, ↑latency/expectoration (phenol red) in ammonia mice.

This modern article further describes the herb as a treatment for “hot syndrome” and shows distinct effects on hyperlipidemia and gut microbiota in mice, relevant to damp-heat metabolism.

A 2024 study found that Coptis chinensis and related formulas reduced cholestatic liver inflammation and cell necrosis, supporting its liver-heat/hepatobiliary use.

This study found that Coptis chinensis altered gut bacteria and fungi, reduced SCFA-producing taxa, and is used clinically for fever, bloating, painful abdomen, and dry stools caused by internal heat.

This article discusses additional anti-influenza constituents from the plant and summarizes continued interest in its flu-related pharmacology.

This study identified Baphicacanthus cusia as a traditional herb used for colds, fever, and influenza, and characterized its major active ingredients.

A screening study on influenza A-infected cells found that aurantiamide acetate from Baphicacanthus cusia root reduced viral effects and inhibited NF-κB-mediated inflammation.

Multi-omics study comparing effectiveness of raw versus processed Glycyrrhiza uralensis formulations in treating chronic fatigue syndrome (CFS) through transcriptomic and metabolomic analysis. Study design: Contemporary investigation comparing raw licorice decoction versus processed licorice formulation efficacy for CFS using multi-omics (metabolomics, transcriptomics) techniques to identify biological pathways and mechanisms. Plant materials: Raw G. uralensis root decoction prepared via traditional method; processed licorice formulation from commercial source. CFS relevance: Traditional and contemporary use of licorice documented for CFS support based on observed improvement in fatigue symptoms and reported HPA axis dysregulation in CFS patients. Results—Processed licorice superior efficacy: Processed licorice formulation demonstrated greater effectiveness compared to raw licorice for CFS symptom improvement—suggesting that processing procedures (often involving honey processing or steaming) enhance bioavailability and bioactivity of anti-fatigue constituents. Results—Transcriptomic changes: Multi-omics analysis identified differential gene expression patterns between raw and processed preparations—processed formulation produced broader transcriptomic changes consistent with enhanced adaptogenic effects. Results—Metabolomic pathway changes: Processed licorice produced metabolomic changes consistent with improved energy metabolism and stress hormone regulation—supporting HPA axis normalization mechanism. Results—Bioavailability enhancement through processing: Data suggest traditional processing methods (steaming, honey-processing) improve absorption and bioactivity of glycyrrhizin and glabridin—explaining superior efficacy of processed formulations in CFS. Results—CFS-specific mechanisms: Identified biological pathways particularly relevant to CFS pathophysiology (HPA axis function, immune regulation, energy metabolism) modulated by processed licorice. Proposed mechanism: Processed licorice enhances glycyrrhizin bioavailability supporting HPA axis regulation and cortisol metabolism; improved polysaccharide absorption supports immune modulation; enhanced glabridin bioavailability supports mitochondrial energy production. Conclusion: Processed Glycyrrhiza uralensis formulations demonstrated superior effectiveness for chronic fatigue syndrome management compared to raw preparations—multi-omics analysis reveals enhanced bioavailability and broader biological pathway modulation supporting HPA axis normalization and energy metabolism improvement through processing-enhanced phytocompound bioactivity.

Comprehensive phytochemical and pharmacological review synthesizing chemical constituents and pharmacological properties of Glycyrrhiza uralensis for traditional uses including energy support, immunomodulation, antioxidant effects, and chronic fatigue syndrome applications. Study design: Systematic literature review of G. uralensis chemistry, pharmacology, and therapeutic applications across traditional and modern medicine. Phytochemical characterization: G. uralensis contains approximately 300 compounds with primary active constituents identified as glycyrrhizin (triterpenoid), glabridin (flavonoid), polysaccharides, and flavonoid glycosides. Glycyrrhizin composition: Triterpene glycoside comprising major sweet-tasting constituent; accounts for ~1-3% dry weight; responsible for adrenal-stimulating and immunomodulatory properties. Glabridin composition: Prenylated chalcone flavonoid; primary hydrophobic fraction constituent; established antioxidant and anti-fatigue properties through oxidative stress reduction and energy metabolism support. Polysaccharide composition: Primary components identified as rhamnose monohydrate, dextran, arabinose, galactose; complex structures with diverse biological activities including immune modulation and antioxidant effects. Results—Polysaccharide antioxidant capacity: G. uralensis polysaccharides demonstrate excellent concentration-dependent hydroxyl radical scavenging and significant DPPH radical scavenging ability—robust antioxidant activity supporting fatigue-associated oxidative stress reduction. Results—Immune enhancement properties: Glycyrrhiza polysaccharides enhance immune activities and reduce oxidative stress in experimental models—supporting adaptogenic and stress-resistance benefits. Results—Phytochemistry-based mechanistic understanding: Multi-compound synergistic action (glycyrrhizin adrenal support, glabridin energy metabolism, polysaccharides immune/antioxidant) provides comprehensive fatigue management through multiplex mechanisms. Results—4000-year phytochemical validation: Modern chemical analysis validates traditional use through identification of established bioactive compounds responsible for documented therapeutic effects. Results—Comparative licorice species efficacy: Different Glycyrrhiza species (G. uralensis, G. glabra, G. inflata) show comparable phytochemistry, explaining parallel therapeutic use across geographic regions and regulatory systems. Results—Chronic fatigue syndrome (CFS) application: Prepared licorice formulations emerging as CFS support strategy based on HPA axis regulation through glycyrrhizin actions and polysaccharide immune enhancement. Conclusion: G. uralensis demonstrates rich phytochemical profile with glycyrrhizin, glabridin, and polysaccharides supporting multiplex anti-fatigue and adaptogenic mechanisms—scientific validation of 4000-year traditional use through modern phytochemical and pharmacological characterization.

Experimental animal model study investigating anti-fatigue effects of glabridin (primary flavonoid constituent from Glycyrrhiza uralensis) on exhaustive exercise capacity, blood lactic acid reduction, and glycogen preservation in mice. Study design: Double-blind, randomized animal model study over 28-day supplementation period; BALB/c male mice receiving glabridin at multiple doses (5, 10, 20 mg/kg) vs placebo; exhaustive swimming exercise protocol assessing endurance capacity; biochemical fatigue markers measured. Intervention protocol: Glabridin doses administered daily via oral gavage for 28 consecutive days; swimming exhaustion protocol with 5% body mass load; blood samples collected pre and post-swimming; organ samples collected for glycogen analysis. Results—Exhaustive exercise time prolongation (major finding): Swimming duration significantly increased in all glabridin treatment groups compared to control (p<0.05): low-dose (5 mg/kg) 22.58% increase, middle-dose (10 mg/kg) 43.55% increase, high-dose (20 mg/kg) 50.04% increase—dose-dependent endurance enhancement. Results—Blood lactic acid (BLA) reduction: Post-swimming BLA concentrations significantly lower in all treatment groups vs control (p<0.05)—glabridin effectively delayed metabolic acidosis accumulation characteristic of fatigue. Results—Liver glycogen preservation (major finding): Post-swimming liver glycogen concentrations elevated in treatment groups (low 12.27 ± 1.06 mg/g, middle 17.38 ± 1.19 mg/g, high 15.43 ± 1.36 mg/g) vs control (7.58 ± 1.21 mg/g) (p<0.05)—energy substrate preservation supporting endurance capacity. Results—Muscle glycogen preservation: Post-swimming muscle glycogen similarly elevated in treatment groups (low 1.75 ± 0.61 mg/g, middle 2.29 ± 0.44 mg/g, high 2.18 ± 0.87 mg/g) vs control (1.17 ± 0.95 mg/g) (p<0.05)—glycogen sparing in muscles supporting endurance and fatigue resistance. Results—Serum BUN reduction: Blood urea nitrogen concentrations significantly reduced in all treatment groups vs control (p<0.05)—indicating reduced protein catabolism and nitrogen waste during exercise, suggesting preservation of muscle protein during fatigue states. Results—No body mass changes: Glabridin had no significant effect on body mass, body mass gain, or food efficiency ratio—fatigue-resistance benefits independent of weight gain or metabolic rate changes. Results—Dose-response relationship: Optimal anti-fatigue effect observed at middle and high doses (10-20 mg/kg) with plateau effect suggesting saturation at high dose. Mechanism proposed: Glabridin (polyphenolic flavonoid) enhances glycogen mobilization and preserves energy substrates during exercise; reduces lactate accumulation through improved metabolic efficiency; protects mitochondrial function from oxidative stress during intense exercise. Conclusion: Glabridin from G. uralensis significantly inhibits fatigue through 22.58-50.04% exhaustive exercise time prolongation, effective BLA delay preventing metabolic acidosis, and substantial glycogen preservation (hepatic and muscular) supporting endurance capacity—establishing phytocompound basis for traditional anti-fatigue use.

Erucic acid from Isatis indigotica suppressed influenza A replication and inflammation in vitro and in vivo through NF-κB and p38 MAPK modulation.

Epigoitrin, an alkaloid from Isatis indigotica, reduced stress-related influenza susceptibility in mice by promoting MAVS signaling and IFN-β production.

This study showed that Isatis indigotica extract and its marker compounds had antiviral activity against Japanese encephalitis virus, supporting broader antiviral potential.

A crude root extract inhibited multiple influenza virus subtypes in vitro, reduced viral attachment/hemagglutination, and worked in the early stage of infection.

Broader nutraceutical review of Chinese yam summarizes historical digestive use and modern evidence for gut protection and microbiota modulation.

Review of Chinese yam bioactives states that yam has a long history in gastrointestinal support and its polysaccharides may help gut health and intestinal disorders.

Experimental study showed yam polysaccharides enhanced intestinal barrier integrity in rat intestinal epithelial cells, supporting a gut-health mechanism.

General overview of the species, including bioactive properties; useful as background but not specific clinical evidence for sluggish digestion.

Analytical/in vitro study found commercially available cinnamon samples inhibited diabetes-related enzymes, with C. cassiashowing the highest α-amylase and aldose reductase inhibition; also flagged coumarin safety issues.

Review of clinical evidence concluded C. cassiaappears to help diabetes at 3–6 g/day, while C. verumremained inconclusive.

Review of eugenol's anti-Candida mechanisms, including ergosterol depletion, biofilm inhibition, and synergy with antifungals; includes animal models of oral/vaginal candidiasis.

In vitro study confirming clove oil and eugenol's fungicidal activity against Candida spp. (MIC 0.25–2 mg/mL), ergosterol-binding mechanism, and synergistic interactions with antiseptics.

Review of eugenol's multidirectional biological activities, including antibacterial, antifungal, anti-inflammatory, and anticancer properties, with emphasis on safety and derivatives.

Comprehensive review of eugenol's anti-inflammatory and antioxidant mechanisms, including NF-κB, COX-2, and cytokine modulation in cellular and animal models.

Review highlighting eugenol's local anesthetic action in dentistry, analgesic effects, and anti-Candida activity in immunosuppressed rat models of oral/vaginal candidiasis.

Mechanistic investigation of comfrey root extract in primary human endothelial cells (HUVECs). Study design: Tested hydroalcoholic comfrey root extract (comfrey-RE) and its mucilage-depleted organic fraction (comfrey-OP) for anti-inflammatory activity using IL-1 stimulation. Methods: Real-time PCR, Western blotting, immunofluorescence, reporter gene assays, COX activity assays. Results: (1) Both extracts dose-dependently inhibited IL-1-induced E-selectin mRNA and protein expression; (2) Comfrey impaired expression of VCAM-1, ICAM-1, and COX-2 but not COX-1 enzymatic activity; (3) Mechanism involves NF-κB inhibition at TWO LEVELS: (a) Upstream: comfrey attenuated IKK phosphorylation and IκBα degradation; (b) Downstream: comfrey suppressed p65 nuclear export and p65 transactivation potential; (4) Active compounds identified via HPLC-LC-MS: allantoin, rosmarinic acid (14.03 mg/100g extract), caffeic acid, protocatechuic acid, globoidnan A (20.02 mg/100g extract). Conclusion: Dual-level NF-κB inhibition explains comfrey's anti-inflammatory efficacy.

Double-blind, randomized, placebo-controlled, multi-centre trial of 120 acute upper or lower back pain patients treated over 5 days. Study design: Patients applied verum cream containing comfrey root fluid extract (1:2, 35.0g, ethanol 60% v/v, <0.35 ppm pyrrolizidine alkaloids) or placebo three times daily, 4g per application. Primary efficacy variable: Area under the curve (AUC) of visual analogue scale (VAS) on active standardized movement. Secondary variables: back pain at rest, pressure algometry, global efficacy assessment, Oswestry Disability Index. Results: Pain intensity on active movement decreased 95.2% in comfrey group (104.8–12.7 mm mean VAS) vs 37.8% in placebo (100.0–56.5 mm), p<0.001. All secondary parameters showed significant superiority for comfrey (p<0.001 all). Notably, fast-acting effect: pain already decreased 33% within 1 hour in comfrey group vs 12% in placebo. Adverse events: 4 comfrey (eczema, cold, nausea, rhinitis) vs 3 placebo (headache, pruritus)—all mild. Conclusion: Comfrey root extract highly effective for acute back pain with fast onset.

Traditional use: Flowers/leaves infusion for cough, bronchitis, sore throat; mucilage soothes mucosa.

Clinical-style article reported aqueous corn silk extract reduced UTI symptoms and improved urine findings, supporting traditional use but with limited evidence strength.

Animal study found corn silk extract altered glomerular function and urinary electrolyte excretion, supporting its diuretic use in urinary disorders.

Review summarized cranberry polyphenols, antiadhesion mechanisms, and microbiota-related pathways for UTI prevention.

Review concluded cranberry has clinical benefit for preventing recurrent UTI in women and likely works by antiadhesion effects of A-type PACs.

Review: P. ternata resolves phlegm in cough/vomiting/ulcers; 212 compounds, TCM formulas for phlegm-damp disorders.

Processed PRP ↓airway inflammation/mucus in cold asthma mice via ↓IL-4/IL-5/IL-13, ↑IL-10/IFN-γ, PKC/EGFR/MAPK/PI3K-Akt inhibition.

P. ternata ↓goblet cells/MUC5AC/IL-1β/TNF-α, ↑ERK inhibition after budesonide withdrawal in COPD rat model.

Ethanolic leaf extract (8 mL TID) ↑urinary frequency (p<0.05) and excretion ratio (p<0.001) in 5h post-doses in humans (n=17).

Dandelion leaf (80% methanol, 80 mg/kg) ↑urine/Na+ excretion comparable to furosemide 10 mg/kg in mice; leaf > root.

A review of clinical studies reported positive effects of Harpagophytum procumbenspreparations in musculoskeletal pain, including osteoarthritis.

A randomized clinical trial showed that Harpagophytum procumbensimproved pain and function in knee osteoarthritis, with outcomes comparable to meloxicam over the study period.

A clinical trial in knee osteoarthritis compared Harpagophytum procumbens with meloxicam and found the herb improved pain and function, supporting its use as a symptom-relief option.

A later review summarized the clinical evidence and found benefit for osteoarthritis and low back pain, but noted that more robust studies were needed.

A review of the evidence concluded that devil’s claw can help with osteoarthritis and low back pain, though results vary across studies and products.

A rheumatology review concluded that devil’s claw extracts with sufficient harpagoside content can help alleviate osteoarthritis pain, though study quality varied.

This multicenter trial found that Harpagophytum procumbensimproved knee and hip osteoarthritis symptoms and was comparable to diacerhein.

A multicenter randomized trial found that Harpagophytum procumbens was at least as effective as diacerhein for hip and knee osteoarthritis, with fewer adverse events and reduced use of rescue analgesics/NSAIDs.

Recent review highlights rosehip’s bioactive compounds and potential immune-supportive, anti-inflammatory, and antioxidant actions.

Animal study found Rosa canina fruit extract increased immune-cell counts and phagocytic activity in rats.

This study assessed iodine intake from red seaweeds including Palmaria palmata and showed that the product can contribute meaningful iodine exposure, which is relevant because iodine intake affects thyroid physiology.

A review of edible seaweeds notes that red seaweeds such as Palmaria palmata are nutrient-rich, but also that health claims are mostly based on in vitro and animal studies rather than strong human thyroid data.

A randomized placebo-controlled trial in healthy adults found that Palmaria palmata-enriched bread increased TSH, triglycerides, and CRP, suggesting it alters thyroid function rather than directly treating hypothyroidism.

This later review states that Ophiopogon japonicus is commonly used to treat dry lung and dry cough, cough due to deficiency, thirst, and insomnia in TCM formulas.

This article discusses an herbal formula containing Ophiopogon japonicus and notes its anti-inflammatory, antioxidant, and lung-moistening properties.

This review notes that Ophiopogon japonicus is used in TCM to moisten the lungs and relieve cough, with pharmacological activities including cough relief and anti-inflammation.

Observational trial found echinacea/sage lozenges reduced throat pain, tonsillopharyngitis symptoms, and viral load in acute sore throat.

Newer clinical trial research continues to evaluate echinacea formulations for acute respiratory infections, supporting possible role in flu-like illness management.

Newer clinical trial work continues to explore echinacea formulations for acute respiratory infections, supporting its role in upper-airway symptom management rather than sinusitis alone.

Systematic review and meta-analysis noted that some echinacea formulations may prevent upper respiratory infections, but overall effects are inconsistent.

Review summarized that echinacea may help reduce the incidence of recurrent respiratory tract infections and complications, but evidence remains variable.

Systematic review and meta-analysis found echinacea might have a preventive effect on upper respiratory tract infections, but results varied across studies.

Clinical trial of atopic (allergic) eczema patients using high-alkylamide E. purpurea cream topically. Alkylamide-rich Echinacea extract showed strong anti-inflammatory effects and epidermal lipid barrier restoration. Topical cream application reduced both pruritis (itchiness) and redness over 85-day trial period, with particularly significant improvement from days 57-85. Results demonstrate anti-allergic efficacy in cutaneous allergic manifestations through restoration of skin barrier function and reduction of allergic inflammation.

In vitro study examining alkylamides from E. purpurea root extract on mast cell function using both bone marrow-derived mast cells and rat basophilic leukemia cell lines. Testing included crude extract, purified alkylamide (dodeca-2E,4E-dienoic acid isobutylamide), and fractions with varying alkylamide content. Results: Inhibition of mast cell degranulation and calcium influx observed with full extract and high-alkylamide fractions, but NOT with low/no-alkylamide fractions. Conclusion: Alkylamides are the active anti-allergic constituents. Combined mast cell + macrophage effects suggest Echinacea potential for allergic inflammation management.

Review of clinical evidence found some products reduced cold incidence and duration, but overall results were mixed and product-specific.

Large randomized placebo-controlled trial found Echinacea purpureareduced total cold episodes, episode days, and painkiller use over 4 months.

Large randomized trial found long-term Echinacea purpureareduced cold episodes and virally confirmed respiratory infections with good safety.

Review of Echinaforce® reports antiviral and immunomodulatory activity and clinical benefit in respiratory tract infections, which can include sinusitis as a complication.

Randomized trial found echinacea did not clearly shorten common cold illness, though there was a small trend toward benefit.

Randomized trial found only a non-significant trend toward lower severity and shorter illness duration with echinacea in common cold.

Randomized placebo-controlled trial found no significant reduction in upper respiratory symptom days with Echinacea purpurea capsules compared with placebo.

Randomized double-blind clinical trial of 90 hospital personnel over 8 weeks during winter months. Groups received either 3 capsules of E. purpurea (twice daily) or placebo (parsley) for 8 weeks. Upper respiratory tract symptoms reported weekly. Results: E. purpurea group reported 9 sick days per person vs. 14 sick days in placebo group. Plant shown to increase phagocytic cells in spleen and bone marrow, acting as immune system enhancer through phytoimmunomodulation affecting polymorphonuclear neutrophil granulocytes and macrophages.

Randomized double-blind trial found echinacea/sage spray was as effective and well tolerated as chlorhexidine/lidocaine for acute sore throat.

Echinacea/sage throat spray study summary reports similar efficacy to standard medication and good tolerability.

Review found mixed trial results for echinacea in prevention/treatment of common cold and influenza-like illness.

Randomized placebo-controlled trial of Echinacea purpurea for treatment of common cold found no significant benefit in symptom duration or severity.

Review of viral respiratory illnesses found elderberry may help reduce symptom duration and severity, especially if taken early.

Review concluded elderberry berries have evidence for reducing cold duration and severity, but results vary by product and study design.

Rapid review concluded elderberry berry preparations may reduce acute respiratory viral symptom duration and severity, including common-cold symptoms.

Review notes elderberry was traditionally used for influenza, colds, and sinusitis, conditions often involving sore throat.

Review concluded elderberry berries have evidence for reducing cold/flu severity and duration, but direct sore-throat-specific evidence is lacking.

Rapid review concluded elderberry berry preparations may reduce flu duration and severity, including fever, congestion, and cough.

Mechanistic study showed elderberry compounds can inhibit influenza virus entry and replication and modulate immune responses.

Review found four clinical trials supporting elderberry berries for cold/flu symptom reduction, but no clinical trial evidence for elder flowers.

Rapid review found elderberry berry preparations may reduce nasal mucous discharge and other acute viral respiratory symptoms when used early.

Review concluded elderberry berries have evidence for reducing cold/flu duration and severity, with direct mucus-membrane evidence still limited.

Review found elderberry berry preparations may reduce duration and severity of common cold and influenza symptoms, including nasal congestion and nasal mucous discharge.

Review concluded elderberry berries have four clinical trials supporting reduced cold/flu duration and severity; elder flowers remain untested in clinical trials.

Meta-analysis found elderberry supplementation effectively reduced upper respiratory symptoms in trials that included common-cold episodes.

Meta-analysis found elderberry reduces upper respiratory symptoms, which may include sore throat as part of respiratory infection symptom clusters.

Meta-analysis reported elderberry supplementation reduced upper respiratory symptoms and seemed more effective for flu than common cold.

Meta-analysis found elderberry supplementation reduced upper respiratory symptoms and was more effective for influenza-type symptoms than common-cold symptoms.

Meta-analysis found elderberry supplementation reduced overall upper respiratory symptoms and could reduce symptoms like nasal congestion and nasal discharge.

Randomized study found oral elderberry extract reduced influenza/common-cold symptom duration and severity.

Randomized influenza trial found elderberry syrup reduced flu symptom duration; sore throat was not a primary endpoint.

Randomized placebo-controlled trial found elderberry syrup reduced influenza symptoms about 4 days earlier than placebo and lowered rescue medication use.

Modern review of clinical and preclinical data described eleuthero as an adaptogen with possible stress-lowering effects, but stressed that human evidence is still inconsistent.

Modern review again mentions respiratory infection prevention and immune effects, but frames them as promising rather than established.

Comprehensive review of root pharmacology again framed E. senticosus as an adaptogen with possible stress/fatigue-related cognitive benefits, but not definitive brain-fog evidence.

Comprehensive review noted root preparations are marketed to reduce fatigue and stress, but stronger trials are still needed.

Historical review of Russian trials found some evidence for prevention of colds and influenza, but also highlighted major limitations in trial quality and reporting.

Clinical/traditional summary states that small studies suggest eleuthero may reduce the severity and length of colds and flu, while noting more rigorous research is needed.

Preclinical work indicated that Eleutherococcus leaf-derived compounds can penetrate the brain and promote dendritic growth, supporting possible memory benefits.

Monograph-style review highlighted traditional use for stress and fatigue, with mixed human evidence and potential for both benefit and no effect depending on the study.

Clinical trial found no added benefit of eleuthero when combined with stress-management training for stress-related fatigue/weakness and impaired concentration.

Review summarized phytochemistry and effects, including adaptogenic and anti-stress properties, but noted the clinical evidence base remains limited.

Review of adaptogens concluded Eleutherococcus senticosus may improve attention, endurance, and mental work capacity under stress, but evidence is heterogeneous.

Randomized, placebo-controlled trial found eleuthero reduced cardiovascular responses to stress in healthy young volunteers.

This animal study reported that bark extract lowered blood pressure and may do so by altering the gut microbiota, especially Parabacteroides.

This study found that male flower extract lowered blood pressure dose-dependently in spontaneously hypertensive rats and activated ACE2–Ang-(1–7)–Mas signaling.

This animal study found that Eucommia ulmoidesextracts lowered blood pressure in spontaneously hypertensive rats, with the effective fraction likely acting through NO, RAS, and Ca2+ pathways.

Review of Taxus genus pharmacology, emphasizing taxane discovery, microtubule stabilization, and anticancer therapeutic potential.

Phytochemical characterization of T. baccata aril; contextualizes taxane-rich tissues and non-poisonous parts, supporting source-link to T. baccata.

Systematic review of taxanes in breast cancer; confirms clinical backbone status and contrasts paclitaxel/docetaxel safety profiles.

Inventory of ~600 taxane metabolites from Taxus spp.; describes microtubule-stabilizing mode of action and chemical diversity relevant to anticancer activity.

Comprehensive review of taxanes (paclitaxel, docetaxel): microtubule stabilization, mitotic arrest, clinical indications, and resistance mechanisms.

Randomized trial found EPO altered FSH and estradiol and improved menopausal symptoms, especially psychological symptoms.

Review of clinical trials in women found EPO may help with PMS, hot flashes, mastalgia, gestational diabetes, and cervical ripening.

Review notes EPO’s gamma-linolenic acid content and prostaglandin-related mechanism may underlie its effects on female symptoms.

Comprehensive modern research analysis of S. tetrandra as therapeutic agent specifically for diabetic kidney disease (DKD), a major cause of end-stage renal disease. Research focus: Exploring molecular mechanisms through which primary active components tetrandrine/sinomenine and fangchinoline exert renal protective effects. Therapeutic pathways identified: (1) Anti-inflammatory response modulation—particularly IL-18/IL-1β downregulation in glomerular endothelial cells and renal tissues; JAK2/STAT3 pathway inhibition; TNF-α reduction; (2) Antioxidant stress antagonism—ROS production reduction; GPX1/SOD2 upregulation; Nrf2/HO-1 pathway activation; malondialdehyde (MDA) reduction; (3) Glomerular endothelial function improvement—C/EBP-α/claudin-5 signaling enhancement; RhoA/ROCK pathway inhibition reducing endothelial permeability; tight junction protein preservation; (4) Podocyte damage modulation—Bax/Bcl-2 ratio optimization; cell apoptosis reduction; proliferation marker Ki67 activation; (5) Lipid metabolism intervention—linoleic acid, arachidonic acid, glycerophospholipid pathway regulation; preventing pathologic lipid accumulation in podocytes. Clinical mechanistic findings: In STZ-induced diabetes rats, 6-week sinomenine treatment significantly ameliorated elevated blood glucose levels and reduced urinary albumin excretion (UAE) values compared to controls. Tetrandrine effectiveness: Significantly downregulated glucose, serum creatinine, proteinuria, and urea nitrogen levels in diabetic rat models; decreased serum IL-6, TNF-α, inducible nitric oxide synthase while increasing anti-inflammatory IL-10. Fangchinoline effectiveness: Downregulated IL-6 and TNF-α through p38 MAPK pathway inhibition; improved glucose, creatinine, and albumin levels. Quality control standard: Chinese Pharmacopoeia (2015 edition) requires total tetrandrine and fangchinoline content ≥1.6% in S. tetrandra. Clinical status: Currently used in TCM formulas for chronic kidney disease treatment; expert consensus in China lists S. tetrandra as recommended treatment option for DKD. Future research needs: Rigorous clinical trials needed to validate efficacy and safety, assess pharmacokinetic properties, establish optimal dosing, and explore enhanced formulation strategies for clinical translation. Conclusion: S. tetrandra's alkaloid components demonstrate multi-target, multi-pathway renal protective effects through anti-inflammatory, antioxidant, endothelial repair, and lipid metabolism mechanisms—providing theoretical basis for DKD therapeutic development.

Triple-blind randomized controlled trial found a combination of fennel and Echium amoenumimproved PMS symptoms and quality of life.

Experimental study found fennel nutraceutical lowered gastric juice volume, acidity, and ulcer index, indicating gastroprotective/anti-ulcer potential.

Comprehensive review notes fennel extracts show antibacterial activity against Helicobacter pylori and Campylobacter jejuni, supporting digestive-health relevance.

Review of botany/phytochemistry/pharmacology notes fennel’s broad traditional use for digestive ailments and documents antispasmodic and anti-inflammatory properties relevant to indigestion.

Randomized placebo-controlled study found fennel extract improved most PMS symptoms over three cycles and was well tolerated.

This recent review discusses fenugreek as a natural therapeutic option for testosterone support and male performance.

This mechanistic review summarizes how fenugreek’s phytochemicals may lower cholesterol through multiple lipid-regulating pathways.

Fenugreek seed extract (500 mg/day, 2 cycles) ↓MDQ scores 32% (irritability, breast tenderness, fatigue) in moderate-severe PMS (n=10 pilot).

This randomized double-blind trial tested a fenugreek extract for effects on plasma and saliva testosterone and reported favorable subjective outcomes.

This review notes that fenugreek supplementation has been shown in hypercholesterolemic animals and humans to reduce total and LDL cholesterol.

This mechanistic animal study found fenugreek improved dyslipidemia, likely by up-regulating LDL receptor gene expression.

This clinical study found that fenugreek seed extract improved free testosterone in most participants and also increased sperm counts.

This clinical trial concluded fenugreek seeds may be an effective complementary treatment for borderline hyperlipidemia.

This randomized clinical trial found fenugreek seed powder significantly reduced total cholesterol, triglycerides, and LDL cholesterol, while HDL cholesterol was not significantly changed.

Fenugreek seed powder (900 mg TID, 2 cycles) ↓pain severity (VAS) and systemic symptoms (fatigue, headache, nausea) in dysmenorrhea (n=101).

This small clinical study in hyperlipidemic subjects found fenugreek seeds had a hypolipidemic effect.

Cochrane review found feverfew may modestly reduce migraine frequency, but overall evidence was low quality and results were mixed across trials.

Randomized multicenter dose-response trial found no significant benefit in the full migraine population, but a dose-dependent effect in a subgroup with frequent migraines.

Systematic review and meta-analysis of 7 RCTs found Boswellia and its extracts reduced pain and stiffness and improved function in osteoarthritis patients.

Pilot randomized placebo-controlled trial found a standardized Boswellia extract improved pain, stiffness, function, radiographic findings, and hs-CRP over 120 days.

Randomized double-blind placebo-controlled crossover trial found Boswellia extract reduced knee pain, increased flexion, and improved walking distance with minor GI adverse effects.

Network pharmacology, cluster analysis, and molecular docking study elucidating U. rhynchophylla-Alisma plantago-aquatica L. (UR-AP) antihypertensive mechanisms through comprehensive target-pathway analysis. Study design: In silico integrative approach combining network pharmacology, cluster analysis, and molecular docking to identify bioactive components, core targets, and signaling pathways of UR-AP in hypertension treatment. Bioinformatic methods: TCMSP, TCMID, DCABM-TCM databases screened 58 bioactive compounds; 322 UR-AP targets identified; 1,141 hypertension-related targets from GeneCards, DisGeNET, OMIM, Drug Bank databases; common target identification via Venn analysis; Protein-Protein Interaction (PPI) network construction; GO/KEGG pathway enrichment analysis; molecular docking validation. Results—Bioactive component identification: Network pharmacology identified 58 bioactive compounds in UR-AP—43 from U. rhynchophylla, 16 from A. plantago-aquatica, 1 common (sitosterol). Primary bioactive components: quercetin (degree = 151), alisol B (degree = 95), alisol,b,23-acetate (degree = 81), kaempferol (degree = 62). Results—Common targets: 143 common targets shared between UR-AP and hypertension identified through Venn analysis. Results—Core target identification: Six core targets identified through PPI network and cluster analysis: MAPK1, IL6, AKT1, VEGFA, EGFR, TP53 (interleukin-6, tumor necrosis factor, RAC-alpha serine/threonine-protein kinase, vascular endothelial growth factor A, epidermal growth factor receptor, cellular tumor antigen p53). Results—Cluster analysis: MCODE identified 6 clusters; cluster 1 (score = 37.023) had highest score with IL6 (degree = 98), TNF (degree = 93), AKT1 (degree = 88), VEGFA (degree = 88) as central nodes. Results—KEGG pathway enrichment: 156 enriched pathways identified; top 5 most important pathways: (1) Fluid shear stress and atherosclerosis (degree = 28)—vascular endothelial laminar shear stress effects on vasodilation; (2) AGE-RAGE signaling in diabetic complications (degree = 28)—oxidative stress and inflammation regulation; (3) PI3K-Akt signaling (degree = 27)—cell proliferation and survival regulation; (4) Lipid and atherosclerosis (degree = 27)—lipid metabolism and plaque formation; (5) Calcium signaling pathway (degree = 25)—vascular tone regulation. Results—Molecular docking validation: 48 receptor-ligand docking combinations tested; 33 groups showed binding energy <-7.0 kcal/mol indicating strong interactions. Results—Five strongest bindings (lowest energy): (1) Alisol B-EGFR (-8.9 kcal/mol—most stable); (2) Beta-sitosterol-EGFR (-8.3 kcal/mol); (3) Alisol,b,23-acetate-EGFR (-8.1 kcal/mol); (4) Tetrahydroalstonine-EGFR (-8.0 kcal/mol); (5) Quercetin-EGFR (-7.9 kcal/mol). Mechanism summary: UR-AP produces antihypertensive effects through synergistic action of quercetin, kaempferol, beta-sitosterol, alisol B, and alisol,b,23-acetate targeting MAPK1, IL6, AKT1, VEGFA, EGFR, TP53 via fluid shear stress-atherosclerosis, AGE-RAGE signaling, PI3K-Akt, and calcium signaling pathways. Conclusion: Network pharmacology-molecular docking integration reveals UR-AP antihypertensive mechanisms involve multi-component, multi-target, multi-pathway coordinated action with strong molecular evidence supporting traditional "liver-kidney synergy" concept in TCM hypertension treatment.

Animal model study investigating U. rhynchophylla Scrophularia Formula (URSF) antihypertensive efficacy in spontaneously hypertensive rats (SHR) using LC-MS phytochemical analysis and metabolomics approach. Study design: Experimental animal research evaluating URSF (medical institution preparation from Shandong University affiliated hospital) efficacy for essential hypertension; LC-MS analysis of material basis; serum non-targeted metabolomics with SHR model. Animal model: Spontaneously hypertensive rats (SHR) receiving URSF treatment via oral administration; blood pressure monitoring and biochemical indicator assessment. Phytochemical analysis: LC-MS spectrometry identified phytochemical composition of URSF with multiple bioactive compounds from U. rhynchophylla and Scrophularia components. Results—Metabolomic biomarker identification: 56 biomarkers were metabolically disturbed in untreated SHR compared to normal control group; URSF intervention showed recovery of 13 biomarkers in optimal extraction method compared to other three extraction approaches. Results—Antihypertensive efficacy: URSF demonstrated clinically significant blood pressure reduction in SHR—effective for treating essential hypertension with measurable systolic and diastolic pressure decreases. Results—Metabolic pathway modulation: LC-MS metabolomics identified 3 key metabolic pathways modulated by URSF: (1) Arachidonic acid metabolism pathway—involved in inflammatory response regulation and vasoconstriction control; (2) Niacin and nicotinamide metabolism pathway—supporting NAD-dependent cellular energy processes and vascular function; (3) Purine metabolism pathway—regulating adenosine signaling relevant to blood pressure homeostasis. Mechanism proposed: URSF antihypertensive efficacy mediated through metabolic pathway reorganization restoring dysregulated biomarkers associated with hypertension pathogenesis. Conclusion: URSF demonstrates antihypertensive efficacy in SHR model through modulation of arachidonic acid, niacin/nicotinamide, and purine metabolism pathways with restoration of 13 dysregulated metabolic biomarkers associated with hypertension.

Traditional ethnomedicinal documentation of Uncaria rhynchophylla (cat's claw, Gou Teng) use for hypertension and cardiovascular diseases across 2000+ years. Historical use—Chinese traditional medicine (2000+ years documented): U. rhynchophylla recorded in classical Chinese medical texts for treating hypertension, dizziness, headaches, and cardiovascular diseases; classified as traditional hepatic-meridian agent targeting liver function. Traditional mechanism: Recognized in TCM as "suppressing wind" and "calming liver yang"—traditional descriptors for blood pressure reduction and hypertension management. Contemporary traditional applications: U. rhynchophylla commonly combined with Alisma plantago-aquatica L. (kidney-meridian agent) forming "liver-kidney synergy" traditional drug pair for hypertension treatment—reflects classic TCM liver-kidney co-therapy strategy. Documented ethnomedicinal preparation: Traditional decoction of U. rhynchophylla root used for cardiovascular support; water-extracted herbal formulations employed for hypertension management. Modern clinical recognition: Current use in Traditional Chinese Medicine hospitals and clinics established as treatment for hypertension; documented efficacy in reducing blood pressure and associated symptoms (dizziness, headaches). Research validation status: Thousands of years traditional use now being validated through modern pharmacological and clinical research. Conclusion: U. rhynchophylla represents botanical remedy with extraordinary 2000+ year ethnomedicinal documentation specifically for hypertension management across multiple generations of TCM practitioners.

This clinical study found raw garlic consumption improved lipid profiles in hyperlipidemic patients, with significant cholesterol reduction after 42 days.

This later review summarizes that garlic remains a promising adjunct for hypertension and may help vascular function.

This trial in hemodialysis patients found garlic powder improved lipid-related and inflammatory cardiovascular markers.

This randomized clinical trial found garlic improved lipid profiles in postmenopausal women with moderate hyperlipidemia, including lower total cholesterol, LDL, and triglycerides.

This review focused on 18 randomized controlled trials and found moderate-quality evidence that aged garlic extract can modestly improve cholesterol-related outcomes.

A systematic review of 18 trials found moderate-quality evidence that standardized aged garlic extract can help lower blood pressure as adjunct therapy.

This study reported decreased total cholesterol after raw garlic consumption for 42 days in people with hyperlipidemia, though the sample was small.

This review of evidence found that garlic supplements may lower blood pressure by about 10 mmHg systolic and 8 mmHg diastolic in some hypertensive patients.

This study showed significant decreases in both systolic and diastolic blood pressure in a dose- and duration-dependent manner.

This review concluded the evidence at that time was not yet convincing, with BP reductions too small to be clinically meaningful in the available studies.

This rat study found garlic reduced hypertension by influencing Na/H exchanger isoform-1 and sodium pump activity, supporting a plausible antihypertensive mechanism.

This pilot human study suggested that people with lower blood pressure were more likely to consume garlic, hinting at a blood-pressure association but not proving causality.

This clinical trial in coronary artery disease patients found garlic significantly reduced total cholesterol and triglycerides while increasing HDL cholesterol.

Comprehensive review describes traditional use of Gastrodia elata for headaches, dizziness, and migraine-related disorders.

Meta-analysis of 16 RCTs found gastrodin significantly reduced migraine pain, frequency, and duration, and was generally safe.

Rat study showed the herb pair increased serotonin and reduced glutamate, supporting a possible anti-migraine mechanism.

Animal study found Ligusticum chuanxiong + Gastrodia elatareduced blood-brain barrier permeability and migraine-related biochemical changes in migraine rats.

Recent summary reported ginger may reduce soreness after running and other forms of exercise-induced muscle damage.

Recent pharmacology review again supports ginger’s anti-inflammatory properties and multiple active pathways.

Review of natural resources for endometriosis discusses ginger as a candidate complementary therapy, with evidence still emerging.

Clinical trial registry describes a randomized, double-blind, placebo-controlled study of ginger root extract for chronic sciatic pain, indicating current research interest.

Recent review again highlights ginger’s anti-inflammatory potential in osteoarthritis and joint degeneration.

Recent review again highlights ginger’s anti-inflammatory potential in osteoarthritis and joint degeneration.

Traditional Chinese medicine review notes clinical effectiveness in osteoarthritis, rheumatoid arthritis, and other inflammatory conditions.

Immunology review detailed molecular anti-inflammatory mechanisms, including NF-κB and cytokine suppression.

Systematic review of research on ginger addition to standard migraine preventive treatments (propranolol and depakote/valproate). Evidence suggests ginger may help reduce frequency and severity of migraine attacks when used as adjunct to preventive medications. Distinguishes between ginger's established acute efficacy versus emerging evidence for adjunctive preventive benefit when combined with standard prophylactic agents. Recommendation for ginger consideration in patients on propranolol/valproate migraine prevention seeking additional symptom reduction.

Review of endometriosis-supportive foods notes ginger’s anti-inflammatory and analgesic properties, but also states direct endometriosis studies are unavailable or very limited.

Systematic review of ginger in gastrointestinal disorders compiled from 2023 literature analysis. Documented that anti-inflammatory, antioxidant, antitumor, and antiulcer effects of ginger have been proven in some studies; however, results are controversial. Analysis noted inconsistency between animal model efficacy and human clinical outcomes. Emphasized need for larger, longer-duration RCTs specifically powered for IBS populations to account for high placebo response rates typical in functional GI disorder trials.

Review of ginger and pain notes prior preclinical work in neuropathic pain and summarizes its analgesic potential.

Review noted ginger’s anti-inflammatory pathways and their relevance to muscle pain and recovery.

Systematic review examining ginger efficacy in IBS and inflammatory bowel disease (IBD) including animal models and limited human trials. Review of mechanistic studies showing ginger and gingerol compounds inhibit TNF-α, IL-6, IL-1β, IL-17, IL-4 synthesis and upregulate IL-10 and TGF-β (anti-inflammatory cytokines) through suppression of Toll-like receptor (TLR) signaling and NF-κB pathways. Animal models demonstrated ginger repair of damaged intestinal epithelial barrier through upregulation of tight junction proteins. Conclusion: While mechanistic evidence supports potential anti-inflammatory benefit in IBS, human clinical trial evidence remains insufficient and contradictory. Authors recommend that RCTs with adequate power and longer duration be conducted before clinical recommendations. Important note: Most evidence is derived from IBD rather than IBS studies.

Rat endometriosis model found ginger extract reduced lesion size and atrophy, though inflammatory cytokines were unchanged.

Systematic review examining ginger efficacy compared with placebo in migraine treatment. Two studies reviewed that directly compared ginger extract vs placebo. Meta-analysis results: (1) Ginger reduced mean pain scores at 2 hours (mean difference -1.27, 95% CI -1.46 to 1.07); (2) Ginger increased proportion of patients who were pain-free at 2 hours (relative risk 1.79, 95% CI 1.04–3.09); (3) Ginger halved the risk of migraine-related nausea and vomiting in all studies (RR 0.50); (4) No increased risk of adverse events associated with ginger. Conclusion: Ginger is safe and effective for acute migraine with pain outcomes at 2h significantly superior to placebo.

Integrative endometriosis guide recommends ginger as a low-risk anti-inflammatory botanical, but notes supporting studies are small.

Clinical review summarized ginger’s pain-lowering evidence and discussed its relevance to exercise-induced soreness and recovery.

Narrative review found ginger helps several pain/inflammation conditions, including osteoarthritis and DOMS, and is generally safe.

Narrative review found ginger helps several pain/inflammation conditions, including osteoarthritis and DOMS, and is generally safe.

Narrative review of pain trials found ginger likely reduces inflammatory pain and supports long-term anti-inflammatory use.

Experimental animal study using IBS-D rat model induced by chemical stimulation (acetic acid) and acute/chronic pressure stimulation. IBS-D rats treated with ginger at various doses (50 or 100 mg/kg p.o.) or rifaximin antibiotic control. Outcomes: Defecation frequency, fecal water content (FWC), abdominal withdrawal reflex (AWR) scores, colonic histopathology, inflammatory markers. Results: Ginger treatment significantly reduced defecation frequency, FWC, and AWR scores. Histopathology showed colonic edema reduction equivalent to rifaximin group. ELISA and RT-qPCR showed ginger inhibited proinflammatory factors (TNF-α, IL-6, iNOS). Western blot demonstrated ginger upregulated IκBα and inhibited p-p65 phosphorylation. HPLC identified 6-gingerol as main active component. Results with 6-gingerol pure compound confirmed anti-inflammatory NF-κB pathway inhibition in colonic epithelial cells (CECs).

Review of clinical evidence from placebo-controlled trials examining ginger's mechanism and clinical efficacy for headache treatment. Documentation of gingerol compounds (6-gingerol and 6-shogaol) exhibiting antipyretic and analgesic effects. These compounds function as potent free radical scavengers and trichloromethyl peroxyl radical (CCl3O2) scavengers (rate constant 10^6 M^-1 s^-1 by pulse radiolysis). Effective at IV and oral dosages of 1.8–3.5 mg/kg and 70–140 mg/kg respectively. Mechanism involves inhibition of spontaneous cyclooxygenase (COX) activity implicated in prostaglandin-mediated pain signaling.

Randomized controlled trial investigating ginger extract efficacy for prophylactic (preventive) migraine treatment. Protocol testing ginger as preventive agent when administered prophylactically between migraine attacks. Results: Ginger extract was NOT effective in decreasing migraine frequency when used in prophylactic manner compared to control. Conclusion: While ginger is effective for acute migraine treatment as add-on to NSAIDs, prophylactic use between attacks does not reduce migraine frequency, distinguishing acute vs preventive efficacy profiles.

Animal neuropathic-pain studies suggest ginger extract and 6-shogaol can reduce pain behavior and provide neuroprotection, supporting a plausible mechanism for sciatic pain.

Comparative effectiveness study of ginger powder vs sumatriptan (FDA-approved migraine triptan) in 100 acute migraine patients. Outcome measures: headache severity reduction at 2 hours, patient satisfaction, adverse effects, treatment continuation willingness at 1-month follow-up. Results: Mean headache severity decreased significantly in both groups at 2 hours with similar efficacy. Ginger powder adverse effects significantly less than sumatriptan. Patient satisfaction similar in both groups. Conclusion: Ginger powder represents effective alternative to sumatriptan with superior tolerability profile and equivalent therapeutic efficacy.

Double-blind placebo-controlled randomized clinical trial (RCT) enrolling 60 patients with episodic migraine (1-6 attacks/month) in emergency room setting. Intervention: 400 mg ginger extract (5% active ingredient) plus 100 mg IV ketoprofen (NSAID) versus placebo (cellulose) plus ketoprofen. Primary outcomes: pain severity and functional status measured at baseline, 0.5, 1, 1.5, and 2 hours. Secondary outcomes: migraine symptoms (photophobia, phonophobia, nausea), treatment satisfaction. Results: Ginger group showed significantly better clinical response after 1 h (p=0.04), 1.5 h (p=0.01), and 2 h (p=0.04). Pain reduction and functional status improvement observed at all timepoints in ginger group. Conclusion: Ginger extract addition to NSAIDs improves acute migraine outcomes as add-on therapy.

Double-blind randomized controlled pilot trial of 45 IBS patients randomly assigned to placebo, 1 gram ginger daily, or 2 grams ginger daily for 28 days. Primary outcomes: IBS Severity Scale (IBS-SS) with 25% reduction defining response, and Adequate Relief Rating Scale (ARRS). Pharmaceutical-grade ginger contained 2.29 mg/g gingerols and 6-shogaols. Results: Placebo showed 57.1% responders (34.8% IBS-SS reduction), 1g ginger showed 46.7% responders (26.4% reduction), and 2g ginger showed 33.3% responders (only 12% reduction). Adequate relief identical in all groups (53.3%). Side effects lower in ginger (16.7%) vs placebo (35.7%). Conclusion: Ginger not superior to placebo; dose-response trend was inverse.

Review summarized anti-oxidative and anti-inflammatory evidence, noting gingerols and shogaols as key active constituents.

Preclinical study showed ginger terpenoids can induce apoptosis in endometrial cancer cells, supporting biological activity in endometrial tissue.

Randomized controlled trial found 11 days of ginger reduced muscle pain after eccentric exercise; heat treatment did not increase the effect.

Animal/in vitro study found gingerol-containing extracts strongly inhibited joint inflammation and protected joint tissue.

Animal/in vitro study found gingerol-containing extracts strongly inhibited joint inflammation and protected joint tissue.

Clinical trial showed ginger essential oil massage reduced knee pain in older adults with osteoarthritis.

Clinical trial showed ginger essential oil massage reduced knee pain in older adults with osteoarthritis.

Review established ginger as an herbal medicinal product with broad anti-inflammatory actions, including COX and LOX inhibition.

Early study showed ginger extract had anti-inflammatory effects and inhibited prostaglandin-related pathways.

Randomized trial found a standardized ginger extract moderately reduced knee osteoarthritis symptoms versus placebo.

Randomized trial found a standardized ginger extract moderately reduced knee osteoarthritis symptoms versus placebo.

Theoretical proposition based on Ayurvedic and Tibb traditional medicine systems; proposes that ginger administration exerts both abortive (acute attack termination) and prophylactic (prevention) effects in migraine headache without side-effects. Proposes mechanism: ginger inhibits thromboxane A2 synthesis and suppresses serotonin-induced vasodilation. Suggests ginger offers advantages over conventional migraine drugs (ergotamine, dihydroergotamine, iprazochrome, pizotifen, diazepam) which have significant side-effects and are prescribed cautiously for limited duration.

Systematic review and meta-analysis of 21 studies found Ginkgo bilobaimproved depression outcomes and showed no increase in adverse events.

Double-blind randomized controlled trial of 26 vitiligo patients divided into treatment and control groups. Control group: Topical desoxymethasone corticosteroid plus placebo. Treatment group: Topical desoxymethasone plus oral Ginkgo biloba extract. Measurements: Melanin index (skin pigmentation measure), VASI score, malondialdehyde (MDA—lipid peroxidation marker), TNF-α (proinflammatory cytokine), CD8+ T cell expression (cytotoxic immune marker), and caspase 3 (apoptosis marker) measured at baseline and post-treatment. Results: Ginkgo biloba + desoxymethasone group showed significantly reduced MDA levels (p<0.05), TNF-α levels (p<0.05), CD8 expression (p<0.05), and caspase 3 levels (p<0.05) compared to desoxymethasone alone. Melanin index and erythema significantly improved in combination group. Conclusion: Ginkgo biloba extract demonstrates significant adjunctive benefits when combined with topical corticosteroids, with favorable clinical and molecular effects through oxidative stress reduction and immune modulation.

Clinical review states there is insufficient evidence to support non-FDA-approved use of ginkgo, and that data for cognitive impairment are contradictory.

Review article noted that ginkgo research on cognition has been inconsistent overall, with some acute improvements in attention and memory but no robust proof for healthy adults.

Randomized trial in elderly patients with depression found adjunctive Ginkgo bilobaextract improved depressive symptoms and serum S100B.

Overview of systematic reviews concluded Ginkgo has clear evidence for mild cognitive impairment and dementia, with dose-dependent effects most evident at 240 mg/day.

Pilot study found Ginkgo bilobaphytosome significantly improved heavy legs and showed a trend toward reduced evening edema in patients with chronic venous disease.

Open-label prospective study in young patients found ginkgolide B combination therapy reduced migraine attack frequency and analgesic use over 1 year.

Study in healthy middle-aged adults found improved working memory performance and changed cortical activity after 14 days of Ginkgo extract.

Open-label prospective pilot clinical trial of 12 participants (ages 12-35 years; initially 18-year age limit, then raised to 35 years to facilitate recruitment). Intervention: Standardized G. biloba extract 60 mg twice daily (BID) for 12 weeks. Primary outcomes: Vitiligo Area Scoring Index (VASI) and Vitiligo European Task Force (VETF) measures evaluated at baseline and week 12. Secondary outcomes: Photographs, safety assessment via serum coagulation factors (platelets, PTT, INR). Results: 11 of 12 participants completed trial with ≥85% protocol adherence. Total VASI score improved by 0.5 points (P = 0.021) from 5.0 to 4.5 (scale: 0=no depigmentation to 100=completely depigmented). Disease progression completely stopped in all participants. Average repigmentation was 15% of vitiliginous lesion area. VETF total vitiligo lesion area decreased 0.4% (P = 0.102 trend) from 5.9 to 5.6. Safety assessment: No adverse coagulation changes. Conclusion: 60 mg G. biloba BID associated with significant VASI improvement, complete disease arrest, and feasibility criteria met for larger RCTs.

Clinical study of Ginkgo bilobacombined with paroxetine reported benefit in depression, suggesting adjunctive use with antidepressants.

Double-blind placebo-controlled randomized clinical trial of 47 vitiligo patients (52 initially enrolled, 5 withdrew for reasons unrelated to study). Treatment groups: Group A received Ginkgo biloba extract 40 mg three times daily (TID); Group B received placebo in similar dose regimen. Duration: 12 weeks. Primary outcomes: Disease progression arrest measured by visual assessment and area/intensity measurements. Secondary outcomes: Repigmentation rates, adverse events. Results: Statistically significant cessation of active depigmentation progression in G. biloba group compared to placebo (P = 0.006). Marked to complete repigmentation observed in 10 of 23 patients (43.5%) in G. biloba group versus 2 of 24 patients (8.3%) in placebo group. All 7 acrofacial vitiligo patients treated with G. biloba showed disease arrest compared to none in placebo group. G. biloba was well tolerated with no serious adverse effects. Conclusion: G. biloba extract appears safe, simple, and fairly effective for arresting vitiligo progression and inducing repigmentation.

Randomized crossover study found 30-day Ginkgo improved neuropsychological outcomes in healthy participants.

Randomized trial in healthy young volunteers found dose-dependent acute cognitive effects of Ginkgo, especially under higher task demands.

Randomized, double-blind, placebo-controlled clinical trial found a venotropic drug containing Ginkgo bilobaextract reduced circulating endothelial cell counts more than placebo, suggesting a beneficial venous wall effect.

Early study in healthy volunteers found acute Ginkgo could affect memory and psychomotor performance, supporting cognitive-enhancement research.

This newer systematic review of cognitive outcomes found that P. ginseng tends to benefit accuracy in secondary memory and some attentional processes, especially in acute studies.

This article reports that ginseng supplementation improved endothelial function and reduced arterial stiffness, supporting use in vascular disorders.

This 2024 review describes emerging evidence that ginseng components may improve cognition in healthy adults, including attention and memory.

This later study in rats showed improved physical recovery and energy utilization in chronic fatigue, supporting an anti-fatigue mechanism in preclinical research.

This later study in rats showed improved physical recovery and energy utilization in chronic fatigue, supporting an anti-fatigue mechanism in preclinical research.

A newer review highlights pro-angiogenic effects of Panax ginseng and its derivatives, showing that the plant may influence vessel growth and repair.

The review summarizes early clinical and preclinical evidence that ginseng may help cardiovascular function, including vasodilation and blood flow regulation.

The paper summarizes that Panax ginseng may lower blood pressure in some settings but can also act neutrally, depending on product and population.

This clinical and preclinical review states that Panax ginseng may improve quality of life, vitality, and energy, particularly during fatigue or stress.

This review of clinical trials notes that many published studies report positive effects, supporting continued study of ginseng for cognition and concentration.

This later review of ginseng and neurological disorders summarizes ongoing evidence that ginseng may help cognition, memory, and brain health.

This clinical and preclinical review concluded that ginseng compounds may reduce fatigue and that the evidence supports use to a certain degree.

This clinical and preclinical review concluded that ginseng compounds may reduce fatigue and that the evidence supports use to a certain degree.

This randomized clinical trial in Korean volunteers with mild cognitive impairment found improved visual memory after 6 months of Panax ginseng.

This systematic review concluded that ginseng is a promising treatment for fatigue, especially in people with chronic illness.

This review of active ginseng components describes potential benefits for cognitive impairment, memory, and neuroprotection, which are relevant to brain fog.

This systematic review focused on ginseng as a fatigue treatment and examined trials using Panax ginseng and Panax quinquefoliuswith self-reported fatigue measures.

This systematic review focused on ginseng as a fatigue treatment and examined trials using Panax ginseng and Panax quinquefoliuswith self-reported fatigue measures.

This review explains that ginseng helps regulate stress-related hormonal and immune changes, which is relevant to burnout physiology.

This meta-analysis found that ginseng supplements may reduce fatigue, though evidence for physical performance was less convincing.

This cancer-fatigue trial reported improvement in fatigue scores with high-dose Asian ginseng, although placebo response was also substantial.

This meta-analysis of randomized trials found a statistically significant improvement in fatigue reduction with ginseng supplements, but no clear benefit for physical performance.

This cancer-fatigue trial reported improvement in fatigue scores with high-dose Asian ginseng, although placebo response was also substantial.

This meta-analysis of randomized trials found a statistically significant improvement in fatigue reduction with ginseng supplements, but no clear benefit for physical performance.

This review notes that ginseng can normalize blood pressure and that low blood pressure may rise toward normal, which is relevant to hypotension.

This randomized controlled trial in idiopathic chronic fatigue found that Panax ginsengreduced fatigue severity and improved mental fatigue measures over 4 weeks.

This randomized trial in idiopathic chronic fatigue found that 1 g and 2 g/day of Panax ginsengimproved fatigue scores versus placebo over 4 weeks.

This randomized trial in idiopathic chronic fatigue found that 1 g and 2 g/day of Panax ginsengimproved fatigue scores versus placebo over 4 weeks.

This review explains that ginsenosides can increase nitric oxide, improve vasomotor tone, and protect endothelial cells, all of which support vascular function.

This small open trial found improved inattention and hyperactivity scores in adolescents with ADHD, which is relevant to poor concentration.

This open-label clinical study in Alzheimer’s disease reported improvements in MMSE and ADAS scores during ginseng treatment, suggesting possible benefits for cognitive function.

This clinical study in Alzheimer’s disease found that 4.5 g/day of Panax ginseng improved MMSE and ADAS cognitive scores during treatment, with the effect fading after discontinuation.